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ABSTRACT
THE ROLE OF THE TUMOR MICROENVIRONMENT IN
WALDENSTRÖM MACROGLOBULINEMIA
By
Weiguo Han
University of New Hampshire

The tumor microenvironment (TME) plays an important role in the initiation,
progression and maintenance of cancer cells and is implicated in cancer cell resistance
to therapy. In Waldenström macroglobulinemia (WM), a B-cell malignancy characterized
by the overproduction of a monoclonal IgM protein, the TME plays an important role in
disease biology by secreting cytokines that promote the malignant phenotype. In
previous work, we have shown that the transcription factor GLI family zinc finger 2
(GLI2) regulates interleukin-6 (IL-6) secretion in the WM TME. IL-6, in turn, promotes
WM growth and IgM secretion by malignant B cells. Tocilizumab/Actemra is an anti-IL6R antibody, which can competitively block IL-6 binding to the IL-6R. In this dissertation,
we investigated the efficacy of targeting the TME using Tocilizumab in a preclinical
mouse model of WM that considers the role of the TME in disease biology.
Furthermore, we screened for novel GLI2 target genes in the TME and identified cluster
of differentiation 40 ligand as a novel GLI2 target gene in the TME. Our data shows that
viii

Tocilizumab therapy results in a reduction in tumor growth rate and IgM secretion in
mice sera. In addition, there was no significant change in mice weight suggesting
Tocilizumab induced no toxicities to the mice. Taken together, our data suggests that
administration of Tocilizumab to tumor bearing mice, results in a significant reduction in
tumor volume and IgM secretion. Therefore, the evaluation of the role of Tocilizumab
alone or in combination with other therapies that target malignant cells in WM patients
may provide therapeutic efficacy. As a single agent, Tocilizumab may alleviate
symptoms associated with IgM. In combination, it may reduce IgM levels and slow the
rate of tumor growth, thereby allowing therapeutic agents that target cancer cells
survival to better induce cell death. Further screening of the role of GLI2 in the TME
identified CD40 ligand (CD40L) as a novel GLI2 target gene. We provide evidence of a
novel pathway controlling the transcriptional activation of CD40 ligand in bone marrowderived stromal cells. CD40L plays an important role in normal and malignant B cell
biology and we found increased Erk phosphorylation and cell growth in malignant B
cells co-cultured with CD40L expressing stromal cells. Further analysis indicated that
GLI2 overexpression induced increased CD40L expression, and conversely, GLI2
knockdown reduced CD40L expression. We demonstrate that GLI2 directly binds and
regulates the activity of the CD40L promoter. Additionally, we found that the CCR3PI3K-AKT signaling modulates GLI2-CD40L axis and GLI2 is required for CCR3PI3K/AKT mediated regulation of CD40L promoter. Finally, co-culture of malignant B
cells with cells stably expressing human CD40L, results in increased Erk
phosphorylation and increased malignant B cell growth indicating CD40L in the TME
promotes malignant B cell activation. Therefore, our studies identify a novel molecular

ix

mechanism of regulation of CD40L by the transcription factor GLI2 in the TME and
suggests that targeting GLI2 may be therapeutically beneficial.
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INTRODUCTION

Introduction to the tumor microenvironment
General introduction of the tumor microenvironment
These are the eight acquired hallmarks of cancer - sustaining proliferative
signaling, evading growth suppressors, resisting cell death, enabling replicative
immortality, inducing angiogenesis, and activating invasion and metastasis,
reprogramming of energy metabolism and evading immune destruction (Hanahan and
Weinberg 2011). Besides these hallmarks, there is another very critical capability that
tumors exhibit: the tumor microenvironment (TME). In addition to our increased
understanding of cancer cell biology over the past decade, cancers are now being
recognized as organs or tissues more and more, instead of being simply defined as just
an individual cell type. From this view point, it is not enough to just study a specialized
cell type, but it is equally important to study the related tumor microenvironment, to
better understand the biology of cancer as a tissue.
The tumor microenvironment is defined as the environment around or in a tumor,
composed of cellular and soluble factors. The cellular factors include cells such as
fibroblasts, a variety of immune cells (regulatory T cells, myeloid-derived suppressor
cells, natural killer/NK-cells, dendritic cells, monocytes, mast cells, T lymphocytes and B
lymphocytes), endothelial cells, stromal cells, as well as cells that comprise the blood
vessels (Balkwill et al. 2012, Hanahan and Weinberg 2011, Hanahan and Coussens
2012). The soluble (non-cellular) factors include the extracellular matrix and the
11

signaling molecules produced by all the cells that support the growth and survival of
cancer cells in the tumor such as a variety of growth factors and cytokines (Joyce and
Fearon 2015, Spill et al. 2016).
The effect between the tumor and the tumor microenvironment is bidirectional:
the tumor cells recruit the cells to surround and form its microenvironment, so they can
change the surrounding microenvironment to better favor their survival and growth. On
the other hand, the microenvironment can affect how the tumor grows and spreads,
while also providing support and protection for the tumor cells.

The general roles of the TME in cancer biology
Among the eight hallmarks of cancer, seven involve contributions by the tumor
microenvironment, except for enabling replicative immortality (Hanahan and Coussens
2012). This suggests that the tumor microenvironment is involved in almost every
aspect of cancer cell growth, survival, disease progression and resistance to therapy.
Over the recent decades, there have been significant advances in our understanding of
the contribution of the tumor microenvironment to cancer cell biology, yet many aspects
of the microenvironment remain poorly understood.
The most fundamental trait of cancer cells relates to their ability to sustain
chronic proliferation (Hanahan and Weinberg 2011). Although oncogenic mutations
drive this trait in most forms of human neoplastic cells, the TME has the ability to
support hyperproliferation of cancer cells (Hanahan and Coussens 2012). Both cellular
and non-cellular factors contribute to this ability of the TME. Among the cellular factors,
12

the outlined cell type is the vascular cells (cells that line blood vessels); mainly
endothelial cells, supporting pericytes, tumor-associated macrophages and vascular
smooth muscle cells. The abnormal interactions between these cells in the regulation of
vascular formation, stabilization, remodeling and function are heavily involved in tumor
angiogenesis (Armulik et al. 2005). Studies in mice models have reported that the
induction of angiogenesis increases the proliferation of cancer cells (Bergers et al.
1999, Hanahan and Folkman 1996). Both clinical trials (Carmeliet and Jain 2011,
Ferrara and Alitalo 1999) and mice models (Parangi et al. 1996) also showed that
inhibition of angiogenesis can reduce the proliferation of cancer cells. Besides the
inhibition of cancer cell proliferation, inhibition of factors that promote angiogenesis also
increased tumor cell and endothelial cell apoptosis (Shaheen et al. 1999).
Other cell types also play essential roles in promoting cancer cell growth and
proliferation. This includes tumor-associated macrophages (TAMs), which are
macrophages that are recruited into the hypoxic environment of cancers, by factors
such as hypoxia inducible factor-1 (HIF-1)-dependent upregulation of the chemokine
receptor CXCR4 (Balkwill et al. 2005, Bingle et al. 2002, Pollard 2004). In this case,
cancer cells attract TAMs into the TME, and sustain their survival. In return, TAMs
produce important mitogens as well as various growth factors and enzymes that
stimulate angiogenesis, in responding to the hypoxic environment of the TME (Bingle et
al. 2002). Cells in the TME favor the proliferation of cancer cells by supplying direct and
indirect growth mediators (Balkwill et al. 2005, Hanahan and Coussens 2012); such as
chemokines, epidermal growth factor (EGF), fibroblast growth factors (FGFs),
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inflammatory cytokines, transforming growth factor-β (TGF-β), tumor necrosis factor-α
(TNF-α), and a variety of interleukins (ILs), such as IL-1β and IL-6 (Balkwill et al. 2005).
The extracellular matrix (ECM) is a major component of the non-cellular factors in
the TME. ECM remodeling is an important mechanism that regulates angiogenesis.
Abnormal ECM dynamics can lead to restructure and dysfunction, both of which could
result in tissue fibrosis and cancer promotion (Lu et al. 2011). Besides this, a variety of
enzymes, such as cysteine proteinases, heparinases, metalloenzymes and serine
proteases, are expressed by immune cells in the TME, which can selectively cleave
cell-cell and cell-ECM adhesion molecules. This cleavage can disable growth
suppressing adhesion complexes that maintain homeostasis (Hanahan and Coussens
2012, Lu et al. 2011, Mohamed and Sloane 2006, Pontiggia et al. 2012, Xu et al. 2009).
Both hypoxia and hypoxia-associated necrosis are involved in cancer cell
metastasis (De Jaeger et al. 1998). This is a critical step for cancer cells to adapt to
hypoxia during disease progression (Dang and Semenza 1999). In particular, this is
regulated by the transcription factor hypoxia inducible factor-1 (HIF-1). Studies focusing
on HIF-1α indicate that the transcriptional activity of HIF-1α is a significant positive
regulator of tumor progression and metastatic potential (Liao et al. 2007). A follow-up
study showed that hypoxia facilitates tumor cell migration, eventually leading to cancer
cell metastasis (Haase 2009, Yang et al. 2008). Other factors like vascular endothelial
growth factor (VEGF) and inducible nitric oxide synthase (iNOS) have also been found
to be involved in angiogenesis and cancer cell progression (Ambs et al. 1998, BrancoPrice et al. 2012, Ziche and Morbidelli 2009). The contribution of hypoxia in tumors and
around blood vessels to cancer metastasis through the regulation by HIF-1, also
14

inducing VEGF and iNOS, by endothelial cells in the TME provides strong evidence that
the TME plays an important role in promoting cancer cell migration and metastasis
(Branco-Price et al. 2012, Chambers et al. 2002, Gupta and Massagué 2006, Hanahan
and Coussens 2012, Takeda et al. 2010).
Another essential role for the TME in cancer biology is its role in promoting
cancer cell resistance to therapy. Cancer treatment includes surgery, chemotherapy,
radiation therapy, immunotherapy, targeted therapy and some other options depending
on the location, type, as well as the stage of the caner. Radiation therapy is a treatment
that uses high doses of radiation to kill cancer cells and/or shrink tumors.
Chemotherapy is a treatment that involves the use of drugs that target proliferating cells
(including cancer cells) to kill cancer cells. More recently, immunotherapy and targeted
therapies have emerged as promising strategies to treat cancer. Immunotherapy utilizes
the patient’s immune system to fight their cancer, while targeted therapy uses specific
drugs, like small-molecule inhibitors or monoclonal antibodies, to target specific
changes, molecules or signaling pathways in cancer cells that help them grow, divide
and spread. Except for surgery, the rest of the treatments all happen in patients and
require a more fundamental understanding of cancer biology to better benefit the
therapeutic outcome of the patient. In all these treatments, the TME plays an important
role in treatment outcome.
In the past, the ability of cancer cells to resist anticancer drugs was mostly
considered to be due to genetic mutations or alterations in gene expression changes in
cancer cells. Changes in gene expression can lead to the encoded protein being
mutated which can affect the uptake and metabolism of anticancer drugs by cancer
15

cells, eventually leading to drug resistance. This type of resistance, acquired drug
resistance, is a result of the long-term exposure to anticancer drugs, causing tumor cells
to develop gene mutations or mechanisms that allow them to resist (Hanahan and
Coussens 2012). Another type of resistance to anticancer drugs stems from the TME,
which allows cancer cells to tolerate anticancer drug-induced stress during the initial
exposure, and this is considered as the first step for cancer cells to survive and
eventually develop acquired drug resistance (Li and Dalton 2006). For anticancer drugs
to work well in the tumor, drugs need to pass through the structure of the tumor
vasculature, the tumor tissue, as well as the blood vessel in the tumor, to reach and kill
the tumor cells. In other words, before the drugs are efficiently delivered to the tumor
cells, they need to pass the barriers imposed by the TME. Anticancer drug used to treat
the same cells from a tumor showed high levels of drug resistance as in the tumor,
while no significant resistance was observed when cancer cells were exposed to the
same drugs in vitro (Teicher et al. 1990). This indicates that the resistance of the tumor
to anticancer drugs can develop through mechanisms provided by the TME, not just the
tumor cells themselves. Currently, more and more studies suggest that the TME
involved around the tumor also mediates tumor resistance to therapy (Dalton 1999,
Galmarini et al. 2007, Hazlehurst et al. 2002, Holohan et al. 2013, Li and Dalton 2006,
Meads et al. 2008, Morin 2003).
TME-associated hypoxia is known to activate genes that are involved in
angiogenesis and cancer cells survival through the HIF-1 (Haase 2009, Pouysségur et
al. 2006, Yang et al. 2008). Several studies have shown that hypoxia can select cells
that are insensitive to p53-mediated apoptosis and cells that are deficient in DNA
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mismatch repair, leading to drug resistance (Graeber et al. 1996, Kondo et al. 2001).
Other studies focused on the proliferation of tumor cells in the TME where they found
that tumor cells that are more distant from blood vessels tend to have a low rate of
proliferation, and anticancer drugs that target cell proliferation are more effective at
targeting and killing proliferating cells more than quiescent cells, which exhibits more
resistance to therapy (Galmarini et al. 2007, Ljungkvist et al. 2002).
Under normal conditions, immune cells recognize, target and kill the cancer cells,
as they can recognize cancer cells’ abnormal activities. However, cancer cells develop
a variety of strategies to avoid being recognized by the immune system. This allows the
tumor cells to evade being destructed by immune cells. These strategies involve a
variety of mechanisms that recruit different cells from the surrounding environment, in
which the TME plays an essential role. In the TME, there are several types of cells that
are involved in the immune escape (cancer cells escaping killing by T cells), including
regulatory T cells, tumor-associated macrophages (TAMs), neutrophils and mast cells
(Ruffell et al. 2010). These cells can block the activity of cytotoxic T lymphocytes and
NK-T cell-mediated killing of neoplastic cells.
Tumor-associated macrophages (TAMs) can differentiate into activated TAMs,
which have the ability to promote tumor escape (escape from being recognized and
killed by CD8+ T cells), when exposed to several immunoregulatory cytokines and other
signaling molecules, such as IL-13 and IL-14 (DeNardo et al. 2011, Doedens et al.
2010, Kryczek et al. 2006, Movahedi et al. 2010, Qian and Pollard 2010). Regulatory T
cells suppress tumor-specific T cell immunity and contribute to the growth of human
tumors in vivo (Curiel et al. 2004). In an indirect manner, tumor cells and tumor17

associated macrophages can recruit regulatory T cells to the tumor to suppress the
immune response through the chemokine CCL22 in the TME (Curiel et al. 2004). In
human breast cancer, tumor-associated macrophages and monocytes have been
reported to be recruited into the TME by mammary epithelial cells via recruitment
factors, such as colony stimulating factor 1 and interleukin-3. These factors together
enhance colony stimulating factor receptor (CSF-R)-dependent macrophage infiltration.
Blocking this macrophage recruitment can improve survival in a mouse model by
slowing primary tumor development and reducing pulmonary metastasis (DeNardo et al.
2011). Regulatory T cells and myeloid-derived suppressor cells are also involved in
immune tolerance induced by the chemokine CCL21, to prevent autoimmunity
(Hanahan and Coussens 2012). CCL21 expression by melanoma tumors in mice is
associated with an immunotolerant microenvironment, which contributes to the
suppression of the immune response by shifting the host immune response from
immunogenic to tolerogenic, to facilitate tumor progression (Shields et al. 2010).
Accumulation of mast cells in the TME can lead to tumor growth and the loss
mast cells correlates with reduced tumor growth. The interaction between mast cells
and the immune environment can mediate immune suppression and contribute to tumor
escape from immune destruction (Wasiuk et al. 2009). This mediation is achieved by
releasing cytokines that recruit cytotoxic T lymphocytes-suppressing myeloid-derived
suppressor cells and regulatory T cells (Hanahan and Coussens 2012).
Cancer-associated fibroblastic cells can produce chemokines and other signaling
molecules that recruit regulatory T cells, myeloid-derived suppressor cells and tumorassociated macrophages into the TME and prevent destruction of cancer cells by host
18

immunity (Hanahan and Coussens 2012). In prostate and breast cancer, cancerassociated fibroblasts support tumor growth and progression by mediating TGF-β
signaling, to inhibit cytotoxic T cell and NK-T cell responses (Hanahan and Coussens
2012, Stover et al. 2007).

Cells in the TME
There are various cell types involved in the TME in cancer biology, including a
variety of immune cells (such as Regulatory T cells, myeloid-derived suppressor cells,
NK-cells, dendritic cells, monocytes/macrophages, mast cells, T lymphocytes and B
lymphocytes), fibroblasts, endothelial cells, stromal cells, as well as cells that comprise
the blood vessels. These cells play different or similar roles in the TME, mostly, their
mechanisms favor cancer cell survival, growth, progression and resistance to therapy.
Immune cells
The immune cells that are recruited to the TME play different roles that apply to
several hallmarks of cancer. These roles can be grouped into two types: cells or factors
produced by cells that directly benefit and those that indirectly benefit cancer cells. The
direct and indirect growth factors from the immune cells, as well as some types of
stromal cells in the TME can stimulate the proliferation of cancer cells (Balkwill et al.
2005). Like the growth factors mentioned before: epidermal growth factor (EGF),
fibroblast growth factors (FGFs), inflammatory cytokines, transforming growth factor-β
(TGF-β), tumor necrosis factor-α (TNF-α), and variety kinds of interleukins (ILs, such as
IL-1β and IL-6) (Balkwill et al. 2005). This is counted as direct benefit toward growth of
19

cancer cells. In addition, studies focused on regulatory T cells and myeloid-derived
suppressor cells show that these two types of cells are major components of the
immune suppressive tumor microenvironment, and they can suppress the natural killer
cells’ ability to carry on their normal function in the tumor, by regulating the TGF-β
signaling pathway (Lindau et al. 2013, Vitale et al. 2014, Yang et al. 2010). CD4+CD25+
regulatory T cells have been reported to be important contributors to the development of
immune tolerance in the tumor and play a critical role in the suppression of anti-tumor
immunity, through suppressive cytokines such as IL-10, IL-35 and TGF-β, to dampen
the NK cell immune responses and to benefit cancer cell growth and survival (Chen et
al. 2016, Ghiringhelli et al. 2006).
Normal cells are “programmed” to die, typically through regulated apoptosis, so
the body can control abnormal proliferation. For cancer cells to stay in their immortal
status of proliferation, they must either develop intrinsic resistance to local cell death
programs or coordinate development of cell extrinsic programs to support their survival
(Hanahan and Coussens 2012). The immune cells in the TME contribute to this
capacity. In breast cancer, vascular cell adhesion molecule-1 (VCAM-1) is reported to
provide a survival advantage to cancer cells that infiltrate leukocyte-rich
microenvironments like the lungs and binds metastasis-associated macrophages to
cancer cells via counter-receptor α4-integrins. In addition, clustering of cell surface
VCAM-1 can trigger Akt activation and protect cancer cells from apoptosis through Ezrin
(which functions as a general cross-linker between plasma membrane proteins and the
actin cytoskeleton) (Chen et al. 2011). Tumor-associated macrophages are also found
to be involved. Increased levels of tumor-associated macrophages and cathepsin
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protease were found in mammary tumors when treated with Taxol chemotherapy, and
cathepsin-expressing macrophages also protected against tumor cell death induced by
several other chemotherapies, such as Etoposide and Doxorubicin (Shree et al. 2011).
These studies show that the immune cells in the TME provide survival signals for
cancer cells which allows them to resist therapy-induced cell death.
One of the hallmarks of the cancer is inducing angiogenesis. In the past, studies
mainly focused on the regulation by cancer cell expression of proangiogenic factors.
More recently, accumulating evidence suggests that cells in the TME are essential
components of chronic angiogenesis in tumor (Hanahan and Coussens 2012). Tumorassociated macrophages are reported to regulate tumor angiogenesis through the
vascular endothelial growth factor A (VEGF-A) in mice. The expression of VEGF-A by
tumor-associated macrophages led to a massive infiltration, into the tumor, of
leukocytes and indicated that macrophage-secreted VEGF regulates malignant
progression through stimulating tumor angiogenesis, leukocytic infiltration and tumor
cells invasion (Lin et al. 2007). Other studies in mouse various models of cancer show
that tumor-associated macrophages also produce MMP-9 to provide an alternative
mechanism to promote angiogenesis, which still dependent on VEGF (Bergers et al.
2000, Du et al. 2008, Giraudo et al. 2004). Beside VEGF, tumor-associated
macrophages can also produce placental growth factor to stimulate tumor angiogenesis.
The host-produced histidine-rich glycoprotein (HRG) can polarize the TAMs to promote
antitumor immune responses and blood vessel normalization, to decrease tumor growth
and metastasis and to enhance chemotherapy (Rolny et al. 2011). Colony stimulating
factor 1 (CSF1) is reported to recruit monocyte/macrophage in response to cytotoxic
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therapies, to enhance CSF1 receptor-dependent macrophage infiltration, and blockade
of macrophage recruitment with CSF1 receptor-signaling antagonists can improve
survival of mammary tumor-bearing mice by slowing primary tumor development, thus
decreasing blood vessel density and reducing metastasis (DeNardo et al. 2011).

Endothelial cells and Stromal cells
Endothelial cells and stromal cells are two major supporting cell types in the
TME. They play different but essential roles in cancer biology; one of these roles is to
favor cancer cell growth and survival. Endothelial cells have been reported to play an
important role in the regulation of vascular formation, stabilization, remodeling and
function, and the abnormal interaction between endothelial cells and mural cells (which
are perivascular cells that include vascular smooth muscle cells and pericytes) can lead
to tumor angiogenesis (Armulik et al. 2005). Furthermore, these cells are also involved
in resisting cell death by cancer cells, conversely, increased apoptosis resulting from
anti-cancer therapies can reduce the rate of angiogenesis (Hanahan and Coussens
2012). Angiogenesis can limit cell death for cancer cells resulting from hypoxia and lack
of serum-derived nutrients and survival factors. This limitation can be blocked by
vascular disrupting agents, like the drug OXi4503 (Daenen et al. 2009).

Fibroblasts
Fibroblasts involved in the TME are mainly tumor- or cancer-associated
fibroblastic cells (CAFs). There are several subtypes of CAFs based on the expression
22

of different surface binding proteins (Hanahan and Coussens 2012). CAFs can express
and secrete different signaling proteins to support cancer cell proliferation, such as
hepatocyte growth factor (Cirri and Chiarugi 2012). CAFs can also contribute to the
proliferation of cancer cells by associating with epithelial-to-mesenchymal transition, via
secretion of the cytokine TGF-β (Chaffer and Weinberg 2011).
Studies on normal tissue fibroblasts indicate that fibroblasts can inhibit the
growth of cancer cells by direct contact with each other, suggesting that normal
fibroblasts play a role in suppressing the growth of cancer cells (Bissell and Hines 2011,
Flaberg et al. 2011). Compared to this, cancer-associated fibroblasts did not suppress
the growth of cancer cells, and conversely, favor the escape of cancer cells from the
growth suppressors. The reason they have lost this suppressor ability may be caused
by them being reprogrammed to CAFs, but the precise mechanism remains unresolved.
Studies on the CAFs have shown that CAFs have the ability to limit the effect of
apoptosis on cancer cells (Kalluri and Zeisberg 2006, Loeffler et al. 2006). This
mechanism involves the secretion of survival factors like insulin-like growth factor-1 and
insulin-like growth factor-2. Furthermore, CAFs are related to the formation of the
extracellular matrix, which contributes survival signals for cancer cells in the TME by
synthesizing the extracellular matrix molecules and the extracellular matrix-remodeling
proteases (Hanahan and Coussens 2012). Studies in breast cancer show that breast
cancer cells co-cultured with mature adipocytes exhibit radioresistance; and this
radioresistant phenotype was driven by the significant increase of the cytokine IL-6 in
the tumor cells, which plays a protective role (Bochet et al. 2011).

23

When looking at angiogenesis as a hallmark of cancer biology, CAFs are also
involved in benefiting tumor tissue angiogenesis. CAFS have been reported to produce
different proangiogenic signaling molecules, such as VEGF, IL-8/CXCL8 and plateletderived growth factor C (PDGF-C) (Hanahan and Coussens 2012). PDGF-C has been
shown to be upregulated in CAFs from resistant tumors and this upregulation of PDGFC can even help some tumors overcome inhibition of VEGF-mediated angiogenesis,
which means PDGF-C can rescue angiogenesis (Crawford et al. 2009). In addition,
CAFs can participate indirectly in angiogenesis by producing chemoattractant to attract
other proangiogenic cells (Räsänen and Vaheri 2010, Vong and Kalluri 2011).
CAFs also modulate and contribute to cancer cell invasion and metastasis.
CAFs-derived TGF-β has been shown to play a role in activating epithelial to
mesenchymal transition and is involved in cancer cell invasion and metastasis (Chaffer
and Weinberg 2011). Mesenchymal stem cells are reported to localize to breast
carcinomas and cause cancer cells to increase their metastatic potency. When bonemarrow-derived human mesenchymal stem cells are mixed with weakly metastatic
human breast cancer cells, the chemokine CCL5 from mesenchymal stem cells, was
found to enhance motility, invasion and metastasis (Karnoub et al. 2007). CAFs have
also been found at the invasive front in some tumors, indicating that the normal tissue
fibroblasts may have been reprogrammed by signaling molecules released by cancer
cells during the process of invasion (Hanahan and Coussens 2012).
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Inflammation is a hallmark of cancer
Tumor-promoting inflammation is one of the enabling characteristics in cancer
besides the eight hallmarks (Hanahan and Weinberg 2011). Inflammation plays an
essential role in cancer cell initiation, proliferation, invasion and metastasis. Indeed, an
inflammatory microenvironment is now considered an essential component of the
majority of cancers (Mantovani et al. 2008). The activation of transcription factors such
as NF-kB, STAT3, and AP-1, by tumor-promoting cytokines which are produced by
immune/inflammatory cells, induce genes that stimulate cell proliferation and survival
and is considered a major tumor-promoting mechanism (Grivennikov et al. 2010). NFƙB has also been reported as a key molecule that is involved in the relationship
between inflammation, tumor promotion and progression (Karin 2006, Karin and Greten
2005). NF-ƙB can regulate the expression of many genes which can suppress tumor
cell death, stimulate cycle progression, enhance epithelial-to-mesenchymal transition
(which plays an important role in tumor invasiveness), and provide newly emerging
tumors with an inflammatory microenvironment that supports cancer cells progression,
invasion of surrounding tissues, angiogenesis and metastasis (Lin and Karin 2007).
There are variety of cytokines produced by immune cells that are involved in tumor
development and progression. Among those cytokines, TNF-α, TNF-related apoptosisinducing ligand (TRAIL), IL-1β, IL-6, IL-10, IL-12, IL-17, IL-23, TGF-β and Interferon-γ
(IFN- γ) have been reported as outlined below (Grivennikov et al. 2010, Lin and Karin
2007).
TNF-α produced by tumor cells or inflammatory cells in the TME can promote
tumor metastatic growth and this promotion depends the NF-ƙB activation in tumor cells
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(Luo et al. 2004). TNF-α has also been reported to be involved in tumor initiation by
stimulating the production of molecules that can lead to DNA damage and mutations
(Hussain et al. 2003). Studies on skin carcinogenesis in mice with a deficiency in TNF-α
show that TNF-α deficient mice were resistant to development of benign and malignant
skin tumors, while there was a much higher percent of wild type mice developed skin
tumors. Furthermore, deletion of a TNF-α inducible chemokine also showed some
resistance to skin tumor development (Moore et al. 1999). Subsequent studies have
shown that the TNF-α receptors, TNFR1 and TNFR2, also have protumor activity in
mice. Tumor multiplicity, the average number of tumors per mouse, was significantly
reduced in mice deficient in TNFR1 and TNFR2 compared to wild type mice. The fact
that TNFR1 deficient mice showing more resistance to the development of skin tumors
than TNFR2 deficient mice indicates that TNFR1 is the major mediator of TNF-αinduced tumor formation (Arnott et al. 2003). Studies on the Mdr2-knock-out mice,
which develop hepatocellular carcinoma (HCC), show that the inflammatory process
triggers hepatocyte NF-ƙB activation through upregulation of TNF-α in adjacent
endothelial and inflammatory cells. Furthermore, anti-TNF-α treatment of IƙB-superrepressor in later stages of tumor development to suppress NF-ƙb signaling resulted in
apoptosis and finally failure to progress to HCC (Pikarsky et al. 2004). Another study in
a murine cancer metastasis model, stimulated with bacterial lipopolysaccharide (LPS),
showed that LPS-induced metastatic growth depends on TNF-α production by host
hematopoietic cells and NF-ƙB activation in tumor cells and stimulates tumor growth in
the lung (Luo et al. 2004). TNF-α can also cooperate with other proinflammatory
cytokines, and together, they contribute to tumor promotion. It has been reported that
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the enhanced production of the tumor promoting cytokines IL-6 and TNF-α, cause
hepatic inflammation and activation of STAT3, to promote HCC development in mice
(Park et al. 2010). These studies report that TNF-α, as a proinflammatory cytokine
produced by both host and tumor cells, plays an important role at different stages of
cancer including cancer initiation, growth, angiogenesis and metastasis.
IL-12 and IL-23 are tumor-promoting proinflammatory heterodimeric cytokines
and belonging to the IL-12 family of proinflammatory cytokines (Langowski et al. 2006,
Watford et al. 2004). These two cytokines share a common subunit and bind to a
common receptor chain, IL-12Rβ1. The IL-12R is composed of IL-12Rβ1 and IL-12Rβ2
while IL-23 binds to a receptor composed of IL-12Rβ1 and IL-23R (Watford et al. 2004).
Their receptors are mainly described to be expressed on T cells, NK cells and NKT cells
(Lin and Karin 2007). Binding of these cytokines to their receptors will activate TYK2
and JAK-STAT (STAT1, STAT3, STAT4 and STAT5) signaling pathways, which
eventually lead to effects on tumor development (Lin and Karin 2007, Watford et al.
2004). IL-12 can be produced by a variety of cells including monocytes, neutrophils and
B cells, and the major producers of IL-12 are macrophages and dendritic cells. In
addition, IL-12 is also produced in a T-cell-dependent manner through the engagement
of antigen-presenting cells with CD40 ligand on the surface of T cells (Watford et al.
2004). IL-23 is produced by activated monocytes, activated antigen-presenting cells,
dendritic cells, macrophages, T cells, B cells and endothelial cells (Lee et al. 2004,
Oppmann et al. 2000, Pirhonen et al. 2002, van Seventer et al. 2002). IL-23 is mainly
produced by tumor-associated macrophages (Kortylewski et al. 2009). Despite the fact
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that IL-12 and IL-23 share a receptor subunit and are produced from several similar
cells, they have different effects on tumor development.
IL-12 has been reported to induce the production of interferon-γ, which favors the
differentiation of T helper 1 cells and forms a link between innate and adaptive immunity
(Trinchieri 2003). In mouse models, IL-12 has a strong anti-tumor activity and induces
regression of tumors depending on its ability to promote Th1 cells and cytotoxic T
lymphocytes (CTLs) response. Furthermore, the Th1 cells promoted by IL-12 can
produce IFN-γ, which in turn contributes to the antitumor activity of IL-12 (Trinchieri
2003). Evidence has shown that there is an increase in the expression of IL-23 in
human tumors, and this increased expression regulates local inflammatory responses in
the TME and infiltration of intra-epithelial lymphocytes (Langowski et al. 2006). IL-12
can promote infiltration of cytotoxic T cells and the resultant antitumor activity, while IL23 promotes inflammation and increases angiogenesis, but reduces CD8 T-cell
infiltration (Langowski et al. 2006). Furthermore, genetic deletion or antibody-mediated
elimination of IL-23 leads to increased infiltration of cytotoxic T cells into the
transformed tissue, which shows a protective effect against chemically induced
carcinogenesis (Langowski et al. 2006). In mice, depletion of IL-23 or IL-23R, results in
transplanted tumor cell growth-restriction (Langowski et al. 2006). IL-23 can also
enhance the proliferation of memory T cells and the production of IFN-γ, IL-12 and TNFα from activated T cells, and the level of INF-γ being produced by IL-23 is lower than
that of IL-12 (Hao and Shan 2006). In murine models of cancer, IL-23 can also act
directly on dendritic cells and possesses potent anti-tumor and anti-metastatic activity
(Hao and Shan 2006). Moreover, IL-23 can also induce IL-17 secretion from activated
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CD4+ T cells and stimulate the proliferation of memory CD4+ T cells. This regulation is
mediated by the activation of JAK2, PI3K/AKT, STAT3 and NF-ƙB signaling pathways
(Hao and Shan 2006). Taken together, these studies show that IL-23 plays complicated
roles in cancer biology and may act as alternative and safer therapeutic agent for
cancer, as IL-12 administration can lead to sever toxic side effects due to the extremely
high levels of IFN-γ it induces (Hao and Shan 2006).
Transforming growth factor β (TGF-β) is another powerful cytokine in the TME.
The role of TGF-β in the TME is complicated and paradoxical. It has immunesuppressing and anti-inflammatory properties, and paradoxically, it can also modulate
processes such as cell invasion, immune regulation, and microenvironment modification
that can favor cancer cell development (Massagué 2008). TGF-β signals mainly through
activation of SMAD transcription factors, and can lead to MAPK activation; Signals from
TGF-β will cause phosphorylation of SMAD proteins, and their eventual translocation
into the nucleus to regulate target gene expression (Massagué 2008). This contributes
to different cellular functions, such as cytostatic effects, cell growth, invasion,
extracellular matrix synthesis, cells cycle arrest and migration (Landskron et al. 2014,
Matsuzaki 2013).
The role of TGF-β in cancer biology is complicated and paradoxical. TGF-β plays
different roles in cells depending on cell type and stage of tumorigenesis. In early
stages, TGF-β acts as a tumor suppressor, inhibiting cell cycle progression and
promoting apoptosis (Landskron et al. 2014). TGF-β can suppress T cell-mediated
autoimmune inflammation and anti-tumor immunity. Furthermore, TGF-β is involved in
the suppressive activity mediated by regulatory T cells (Becker et al. 2006). In colon
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cancer mouse model, both TGF-β1- and SMAD3-deficient mice show increased colon
carcinogenesis (Engle et al. 2002, Maggio-Price et al. 2006). Studies from a TGF-β
receptor II-deficient mouse model found that epithelia, such as rectal and genital
epithelia, developed spontaneous squamous cell carcinomas. Moreover, this
progression was associated with a reduction in apoptosis and could be accelerated by
Ras mutations, suggesting that deficient TGF-β signaling pathway contributes to
tumorigenesis (Guasch et al. 2007). Despite the role of TGF-β in anti-inflammatory and
growth inhibition of early stages of cancer, it is also involved in enhancing tumor
progression. In developing and progressing carcinomas, carcinoma cells emerge from
the epithelial-mesenchymal transition (EMT) stimulated by TGF-β providing a selective
advantage to growing carcinoma cells, such as enhanced cell migration and invasion,
heightened resistance to cytotoxic agents, targeted chemotherapeutic and radiation
treatments, and boosted expansion of cancer-initiating and stem-like cells populations
that underlie tumor metastasis and disease recurrence (Morrison et al. 2013). In
addition, TGF-β has been shown in mouse models of skin carcinomas to favor tumor
cells invasion (Derynck et al. 2001). There is evidence that TGF-β inhibits tumor-specific
CD8+ T cells to favor angiogenesis and promote tumor development (Chen et al. 2005).
Increased expression of TGF-β mRNA and protein has also been observed in gastric
carcinoma, non-small cell lung cancer and prostate cancer (Massagué 2008). Taken
together, these studies indicate that the role of TGF-β in the TME is complicated and
paradoxical, and special therapy targeting this cytokine or related signaling pathway
may advance cancer patients.
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The inflammatory cytokine interleukin-6 (IL-6) can mediate the differentiation of
lymphocytes, promote cell proliferation, and cell survival despite apoptotic signals
(Heinrich et al. 1998, Kamimura et al. 2004). IL-6 plays a key role in promoting cell
proliferation and inhibition of apoptosis via activation of the JAK/STAT signaling
pathway upon binding to its receptor (IL-6Rα) and coreceptor gp130 (Hodge et al.
2005). Activation of gp130 triggers the phosphorylation of the proteins STAT1 and
STAT3 for by the Janus associated kinase 1 (JAK1) (Lin and Karin 2007). This
molecular activity eventually leads to activation of specific target genes in the nucleus
(O'Shea et al. 2002). Studies on IL-6 target genes show that most of them are involved
in cell cycle progression and suppression of apoptosis (Haura et al. 2005). This
highlights the important role of IL-6 in tumorigenesis.
In the plasma cell cancer multiple myeloma (MM), IL-6 signaling through IL6R/STAT3 contributes to the pathogenesis of MM, and blockage of the IL-6R/STAT3
signaling pathway leads to the induction of apoptosis (Chatterjee et al. 2004). It is also
suggested that IL-6 plays a pivotal role in the pathogenesis of MM (Bommert et al.
2006) and IL-6 secreted by bone marrow stromal cells in MM can enhance the
interaction between these two cells and lead to the promotion of proliferation of MM
cells (Chauhan et al. 1996). In addition, IL-6 stimulation induces the phosphorylation of
insulin-like growth factor-I and high expression of IL-6Rα in human myeloma cells. Both
of these colocalize to lipid rafts to promote tumorigenesis in response to IL-6 in human
myeloma cells (Abroun et al. 2004). In bone marrow stromal cells, IL-6 has been
reported to be regulated by the chemokine CCL5, at the level of both gene expression
and protein secretion in stromal cells. This in turn, induces immunoglobulin (Ig)
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secretion by malignant B cells in the surrounding bone marrow microenvironment
(Elsawa et al. 2011b). Subsequent studies show that the IL-6Rα subunit, which binds IL6 to activate the IL-6 signaling pathway, is a downstream target of the transcription
factor GLI2. This regulation was found to promote IgM secretion in the B-cell lymphoma
Waldenström macroglobulinemia (WM) (Jackson et al. 2015). In IL-6-deficient mice,
loss of IL-6 resulted in complete resistance to plasma cell tumor development (Hilbert et
al. 1995) and abnormal regulation of IL-6 was shown to increase the risk of
development of Hodgkin lymphoma (Cozen et al. 2004). These studies indicate the
essential role of IL-6 in the development and maintenance of B cell neoplasms.
IL-6 has also been found to play an important role in cancer stem cells (CSCs)
where it promotes the conversion of noncancer stem cells into cancer stem cells. IL-6
secreted from noncancer stem cells cultured in ultra-low attachment plates, can regulate
CSCs-associated OCT-4 gene expression through the IL-6-JAK1-STAT3 signal
transduction pathway in non-CSCs, which promote the conversion of non-CSCs into
CSCs; Inhibition of the IL-6-JAK1-STAT3 signaling pathway with anti-IL-6 antibody
effectively prevented OCT-4 gene expression and prevented non-CSCs converting into
CSCs (Kim et al. 2013).
In colon cancer, IL-6 was reported to be involved in TGF-β signaling in T cells,
thereby regulating STAT-3 activation in tumor cells and this signaling in tumor infiltrating
T lymphocytes controls the growth of dysplastic epithelial cells in colon cancer;
Moreover, IL-6 signaling requires cancer cell-derived soluble IL-6R rather than
membrane bound IL-6R (IL-6 trans-signaling) (Becker et al. 2004). IL-6 trans-signaling
is critically involved in the maintenance of disease state, by promoting the switch from
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acute to chronic inflammation in colon cancer, as well as other types of cancers (Rose‐
John et al. 2006).
These findings along with other studies address the essential role of IL-6 as an
inflammatory cytokine in promoting cancer cell growth, survival, progression and
metastasis. It also provides the rationale to propose IL-6 as a therapeutic target in
cancer. Clinical trials using Siltuximab (CNTO 328), a monoclonal antibody against IL-6,
have shown promising results for non-small cell lung cancer, ovarian cancer, prostate
cancer, and MM (Landskron et al. 2014).

Waldenström macroglobulinemia (WM)
Waldenström macroglobulinemia (WM) is a rare blood cancer characterized by
an excess of abnormal white blood cells called lymphoplasmacytic cells in the bone
marrow. It is also known as lymphoplasmacytic lymphoma (LPL), which belongs to the
non-Hodgkin lymphoma (NHL) family. The World Health Organization (WHO) classifies
it as a subset of a low-grade, non-Hodgkin lymphoma with unique pathologic
characteristics such as monoclonal IgM secretion and infiltration of the bone marrow by
clonal lymphoplasmacytic cells (Treon et al. 2009). WM is thought to be driven by
genetic mutations. The most common somatic mutations are found in MYD88
(MYD88L256P) and CXCR4 WHIM-like mutations (CXCR4WHIM). MYD88 mutation is
found in more than 90% of WM patients and CXCR4-WHIM like is mutated between
30% to 35% of patients (most of them also have the MYD88 mutation) (Treon et al.
2015b).
33

Disease biology
WM accounts for approximately 2% of hematologic cancers, affecting
approximately 1,500 Americans each year and is a slow-growing cancer (Dimopoulos
and Alexanian 1994). The median age at diagnosis is approximately 65 years, with a
slight male predisposition (Rajkumar et al. 2006). Splenomegaly and lymphadenopathy
are uncommon at initial presentation, but at late stages, extramedullary disease is more
common (up to 60% of patients) (Treon et al. 2015b). The typical symptoms for patients
with WM at presentation are weakness, bleeding (usually in the form of chronic
epistaxis and gingival oozing) and fatigue due to anemia (Ghobrial and Witzig 2004,
Rajkumar et al. 2006). The fatigue is usually caused by anemia and the bleeding is
caused by serum hyperviscosity (this is related to the excess IgM, which can thicken
blood and impair circulation) (Ghobrial and Witzig 2004). Hyperviscosity resulting from
high levels of IgM protein can lead to impairment of microcirculation in the central
nervous system, and this may result in epistaxis, headache, blurring or loss of vision,
dizziness and difficulty coordinating movements (Sahin et al. 2014). In some patients,
the overproduced monoclonal IgM protein can clump together, causing a condition
known as cryoglobulinemia, which causes the fingers and toes turn white or blue. The
IgM protein can also circulate in the body and build up in organs like heart and kidneys,
causing a condition called amyloidosis, which can lead to heart and kidney problems
(Gertz et al. 1993, Ghobrial et al. 2003). Lymphadenopathy (enlarged lymph nodes) and
splenomegaly (enlarged spleen) are found in around 25% of cases, which are not as
high as in other non-Hodgkin lymphomas (Ghobrial and Witzig 2004). Other clinical
symptoms may include constitutional symptoms (such as fever, night sweats and weight
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loss), cryoglobulinemia and sensorimotor peripheral neuropathy (Ghobrial and Witzig
2004, Rajkumar et al. 2006). The reason for peripheral neuropathy is currently
uncertain. Other features of WM are due to the accumulation of lymphoplasmacytic cells
in different tissues. Accumulation of these cells can lead to an enlarged liver, spleen or
lymph nodes. Patients with WM have an increased risk of developing other
malignancies in the blood or other tissues. Some affected patients have elevated levels
of IgM and lymphoplasmacytic cells, but there are no other symptoms. Criteria for
diagnosis require a serum monoclonal IgM protein ≥ 30 g/L and >20% bone marrow
infiltration with malignant lymphocytes (García-Sanz et al. 2001). However, the IgM
protein level is not sufficient for the diagnosis of WM, since there are other malignant
cells that can produce IgM (Sahin et al. 2014). Therefore, in clinical practice, elevated
expression of several cell surface markers, such as CD19, CD20 and Ig light chain, in
association with non-paratrabecular pattern of bone marrow infiltration are used for WM
diagnosis (Dimopoulos et al. 2005, Dimopoulos et al. 2000, Ghobrial and Witzig 2004).

Therapy for WM
In the clinical setting, there is no standard-of-care for the treatment of WM.
Initiation of therapy is not be based on the level of the IgM protein, but instead is based
mainly on signs and symptoms (Dimopoulos et al. 2009, Ghobrial 2012). Patients with
disease-related cytopenia, bulky adenopathy or organomegaly, symptomatic
hyperviscosity, severe neuropathy, amyloidosis, cryoglobulinemia, cold agglutinin
disease, or evidence of disease transformation should be considered for immediate
therapy, and asymptomatic patients with WM do not require therapy (Dimopoulos et al.
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2009). Treatment decisions are based on the presence of symptoms, patient factors
(such as age and functional status) and disease factors including the presence of
cytopenia, rate of disease progression, the level of IgM protein, the presence of
neuropathy, cryoglobulinemia and hyperviscosity (Sahin et al. 2014).
Current treatments for WM include the use of alkylating agents, nucleoside
analogs, the monoclonal antibody rituximab, the proteasome inhibitor bortezomib and
the Bruton tyrosine kinase (BTK) inhibitor Ibrutinib (Dimopoulos et al. 2009, Treon et al.
2009). Ibrutinib is the first drug approved specifically for WM by the Food and Drug
Administration after a clinical trial showed impressive responses in previously treated
WM patients (Chakraborty et al. 2015). Another treatment is plasma exchange, to
alleviate the hypervicosity associated with WM. When IgM exceeds 4000 mg/dl,
symptoms of hyperviscosity are generally present and include epistaxis, gingival
bleeding and visual change (Sahin et al. 2014).
Rituximab is widely used for the treatment of WM, either as a single therapy or in
combination with other chemotherapeutic agents. Rituximab is a monoclonal antibody
that targets the molecule CD20 on the surface of B lymphocytes. In a phase II study that
included untreated symptomatic patients with WM who received a combination of
dexamethasone, rituximab and cyclophosphamide (DRC), results showed that 83% of
patients achieved a response, including 7% complete, 67% partial and 9% minor
responses. The median time to response was 4.1 months. The two-year progressionfree survival rate was 90% (Dimopoulos et al. 2007). Another study that used the
combination of rituximab and CHOP (Cyclophosphamide, Doxorubicin, Vincristine, and
Prednisone; R-CHOP) administered every 3 weeks at standard doses, showed that the
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R-CHOP combination achieved a partial response in 91% of patients with a median
response time of 1.6 months, which was much more rapid (Abonour et al. 2007). These
studies indicate that combining rituximab with other chemotherapies is highly effective
as first-line treatments.
Ibrutinib as the first FDA approved drug for the treatment of WM, has been
shown to be highly active, and is associated with durable responses and is safe in
pretreated patients with WM (Treon et al. 2015a). Treon et al performed a clinical trial
with Ibrutinib with Initial ibrutinib dose at a daily dose of 420mg administered orally for
26 4-week cycles. After administration of ibrutinib, the median serum IgM decreased
from 3520 to 880 mg/dL, median hemoglobin levels increased from 10.5 to 13.8 g/dL,
and bone marrow involvement decreased from 60% to 25%. The overall response and
major response rate were 90.5% and 73.0%. The highest overall response and major
response were observed in patients with MYD88L256PCXCR4WT (100% overall response
and 91.2% major response), followed by patients with MYD88L256PCXCR4WHIM (85.7%
and 61.9%, respectively) and patients with MYD88WTCXCR4WHIM (71.4% and 28.6%,
respectively). The estimated 2-year progression-free and overall survival rates among
all patients were 69.1% and 95.2% (Treon et al. 2015a). Toxicities were moderate and
grade 2 or higher were observed in WM, including neutropenia (22% of the patients)
and thrombocytopenia (14%), which were more common in heavily pretreated patients;
atrial fibrillation (5%) in patients associated with a history of arrhythmia, epistaxis (3%)
associated with the use of fish-oil supplements and postprocedural bleeding (3%)
(Treon et al. 2015a).
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The role of bone marrow (BM) TME in WM
The tumor microenvironment facilitates the growth, survival, progression and
metastasis of tumor cells, through different mechanisms. The interaction between tumor
cells and stromal cells, tumor and tumor cells, and tumor cells and the extracellular
matrix, all contribute to disease biology. Additionally, soluble molecules provide further
signals for tumor cell growth and survival (Li and Dalton 2006).
For hematologic malignancies, such as acute and chronic leukemias,
lymphomas, multiple myeloma and WM, they occur in cells from blood-forming tissue,
such as the bone marrow (BM). Therefore, the TME in these malignancies mostly would
be refer as bone marrow tumor microenvironment (BM TME). WM is characterized by
specific homing and tumor growth within the bone marrow niches, and indeed, the BM
TME is involved in tumor cell growth, survival and drug resistance (Dimopoulos et al.
2005, Dimopoulos et al. 2000, Elsawa et al. 2011a, Elsawa et al. 2006, Elsawa et al.
2011b, Ghobrial et al. 2011, Ghobrial and Witzig 2004, Owen et al. 2003).
There are a growing number of studies that focus on understanding the role of
BM TME in WM disease biology, specifically on BM cells, cytokines and growth factors
that are involved. The interactions between BM TME and WM cells not only facilitates
WM cell growth, but also provides a protective role against drug treatment for WM cells.
The BM TME has been specialized into two distinct niches, the “endosteal niche”
and “vascular niche” (Mendelson and Frenette 2014, Sipkins et al. 2005, Yin and Li
2006). The endosteal niche is localized at the interface of the trabecular bone with the
BM, and cells of endosteal niche including osteoblasts maintain the self-renewal
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capacity of the hematopoietic stem cells (HSCs) and regulate their function, which plays
an essential role to sustain the quiescent state of the HSCs (Jalali and Ansell 2016).
The vascular niche supports proliferation and differentiation of the HSCs (Jalali and
Ansell 2016, Sugiyama and Nagasawa 2012). The interaction between BM cells and the
HSCs allows the HSCs to develop, egress into the peripheral blood, home and further
localize into the BM niches at distant sites (Ghobrial et al. 2011).
In the bone marrow TME, the cellular factors consist of a variety of immune cells
and non-immune cells, which include T lymphocytes, B lymphocytes, dendritic cells,
myeloid-derived suppressor cells, mast cells, bone marrow stromal cells and endothelial
cells. Although the functions and contributions of these cells to WM biology have not
been fully investigated, more studies have focused on understanding the contributions
of these cells to WM biology.
Of particular interest in the BM TME, bone marrow stromal cells have been
shown to play an important role in WM cell growth, survival and resistance to therapy. In
this dissertation, we found that coculture of WM cells with CD40L-expresing stromal
cells increased Erk phosphorylation and ultimately cell growth in WM cells. Coculture of
WM cells with stromal cells leads to resistance to various chemotherapies (Leleu et al.
2007, Ngo et al. 2009, Roccaro et al. 2010). Moreover, in bone marrow malignancies,
such as multiple myeloma and WM, bone marrow stromal cells play an important role in
malignant cell biology by secreting a variety of cytokines that are used by malignant
cells to survival and proliferate (Azab et al. 2012a, Burger and Gandhi 2009, Burger and
Peled 2009, Cheung and Van Ness 2001, Elsawa et al. 2006, Elsawa et al. 2011b,
Kurtova et al. 2009b).
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Mast cell hyperplasia is one of the characteristics of WM disease (Jalali and
Ansell 2016). Mast cells are commonly found associated with lymphoplasmacytic cells
in WM patients and provide growth and survival signals for lymphoplasmacytic cells
(Santos et al. 2006). A study on bone marrow mast cells in WM found that CD52 is
widely expressed on bone marrow mast cells, and leads to high levels of alemtuzumabmediated, antibody-dependent, cell-mediated cytotoxicity against bone marrow mast
cells from patients with WM, indicating that bone marrow cells can be targeted in the
treatment of WM and other mast cell-related disorders, as bone marrow mast cells play
a role in supporting growth and survival of WM cells (Santos et al. 2006). Another study
on bone marrow mast cells in WM showed that coculture of sublethally irradiated
autologous bone marrow mast cells along with bone marrow lymphoplasmacytic cells
from WM patients resulted in mast-cell dose-dependent tumor colony formation and
proliferation (Tournilhac et al. 2006). Furthermore, CD40 ligand (CD40L), a potent
inducer of B cell expansion, was found to be expressed on bone marrow mast cells from
WM patients while mast cells from healthy donors did not express CD40L. Moreover,
mast cells induced-expansion of lymphoplasmacytic cells was blocked using a CD40L
blocking protein in a dose dependent manner by. This indicates that in WM, mast cells
support WM cell expansion by activating CD40-CD40L signaling (Tournilhac et al.
2006). In a novel in vivo model of human WM using severe combined immunodeficient
(SCID) mice, and human fetal bone chips, from which WM cells from patient bone
marrow are engrafted directly into the human bone chips to mimic the bone marrow
microenvironment (termed SCID-hu mice), human monoclonal IgM protein, which is
produced by WM cells in SCID-hu mice, was detectable in mice sera, and mast cells
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were observed infiltrating the BM TME, further indicating that mast cells play an
essential role in promoting WM cell growth (Tassone et al. 2005).
Endothelial cells have also been shown to interact with WM cells and play a
critical role in the bone marrow microenvironment in WM. Endothelial cells are mainly
involved in angiogenesis and angiogenesis represents an essential step in cell
proliferation and expansion in several hematologic malignancies, including multiple
myeloma (Vacca and Ribatti 2005) and WM (Terpos et al. 2009). Indeed, in WM, the
bone marrow microvessel density is increased in 30%-40% of patients, and angiogenic
cytokines, such as angiogenin, vascular endothelial growth factor (VEGF), and basic
fibroblast growth factor (FGF) are increased in the serum of WM patients. In addition,
both macrophages and mast cells, which have angiogenic properties, are increased in
the WM bone marrow microenvironment (Terpos et al. 2009). Studies using primary
WM endothelial cells show that endothelial cells in WM patients are present and
express high levels of the ephrin receptors (Eph), which are important regulators of cell
adhesion, cell proliferation, cell cycle and tumor progression, indicating the important
role of endothelial cells in WM. Eph-B2 receptor was found to be activated in WM
patients compared with controls and activate cell adhesion signaling. Furthermore, EphB2 ligand was highly expressed on endothelial cells and bone marrow stromal cells
isolated from WM patients and induced signaling in endothelial cells promoting
adhesion and angiogenesis. Finally, blocking ephrin-B2 or Eph-B2 mediated signaling
inhibited cell adhesion, cytoskeletal signaling, proliferation and cell cycle in WM cells,
which was induced by coculture with endothelial cells. This decreased WM progression
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in vivo (Azab et al. 2012b). Taken together, these studies indicate the importance of
endothelial cells as a component of the TME in WM.
Another important component of the bone marrow microenvironment is cytokines
that are present and/or produced in the BM microenvironment. Cytokines are known to
regulate many biological processes in normal lymphocyte development including
immunoglobulin production, and the presence of cytokines within the BM
microenvironment of WM is likely to contribute to malignant cell growth, survival and
immunoglobulin production, indicating that cytokines are key regulators in the BM
microenvironment of WM (Elsawa and Ansell 2009). Several cytokines are known to be
key regulators of B-cell homeostasis and play an important role in normal B-cell
development. One of the cytokines with an established role is IL-21. B cells
development and function are regulated by IL-21 and IL-21 can induce B cell
proliferation, differentiation into Ig-producing plasma cells, or apoptosis in both mice and
humans. Moreover, IL-21 alone and in combination with Th cell-derived cytokines, can
regulate class switch recombination (CSR) to IgG, IgA, or IgE isotypes, indicating its
important role in shaping the effector function of B cells (Konforte et al. 2009). Another
cytokine, IL-7, has been reported to play an important role in B-cell development
(Nagasawa 2006). IL-7 signaling can drive B-cell specification and commitment in the
BM (Elsawa and Ansell 2009). Cytokines are required to maintain the normal functions
of B-cells and the overexpression of many of these cytokines in may stimulate
dysregulated B-cell proliferation or immunoglobulin production and results in malignant
B cells growth.
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The proinflammatory cytokine IL-6, plays an essential role in normal B-cell
proliferation and maturation and also induces Ig secretion by these normal B cells
(Kishimoto and Tanaka 2015). Stimulation of WM cells with IL-6 has been reported to
increase IgM secretion, and in combination with B-lymphocyte stimulator, IL-6 induced
even higher levels of IgM secretion by WM cells (Elsawa et al. 2006). Elsawa et al. used
a multiplex-bead based array assay to screen cytokines from healthy and WM patients’
sera and bone marrow biopsies, and identified several different dysregulated cytokines
including CCL5, granulocyte colony-stimulating factor (G-CSF), soluble IL-2 receptor,
and IL-6, which were significantly elevated in WM patients whereas IL-8 and epidermal
growth factor (EGF) levels were significantly lower in these patients compared to
healthy controls. CCL5 is correlated with features of WM aggressiveness such as
elevated IgM levels and bone marrow involvement with lymphoplasmacytic cells.
Furthermore, functional analysis revealed a correlation between CCL5 levels and IL-6
levels (Elsawa et al. 2011b). CCL5 was found to stimulate IL-6 secretion in WM bone
marrow stromal cells resulting in increased IgM secretion by WM cells via the
JAK/STAT signaling pathway. These studies define a novel signaling network in the WM
BM microenvironment that regulates IgM secretion by malignant B cells (Elsawa et al.
2011b). IL-6 is a proinflammatory cytokine with a well-defined role in normal and
malignant B-cell biology. IL-6 has been shown to be involved in several B-cell
malignancies including diffuse large B-cell lymphoma, Hodgkin lymphoma and multiple
myeloma (Aldinucci et al. 2004, Arendt et al. 2002, French et al. 2003, Pedersen et al.
2005). Subsequent studies about the role of IL-6 in promoting IgM secretion in WM cells
demonstrated that the oncogenic transcription factor GLI2 in the WM BM
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microenvironment mediates the regulation of IL-6 by CCL5 (Elsawa et al. 2011b). In the
malignant cells, GLI2 was found to modulate the transcription and surface expression of
the IL-6 receptor (IL-6R) (Jackson et al. 2015). Since IL-6 regulates Ig secretion, it was
found that inhibition of GLI2 and/or IL-6R reduces IgM secretion by WM cells. This study
identified IL-6Rα as a downstream target of GLI2 mediating the regulation of IgM
secretion (Jackson et al. 2015). Taken together, these studies indicate that cytokines
within the WM BM microenvironment contribute to malignant B cells activation, growth,
survival, as well as IgM production.
These studies led us to investigate the role of cytokines in the WM TME and how
they mediate the interaction between WM cells and cells in the surrounding BM
microenvironment. Furthermore, this led us to investigate the molecular mechanisms by
which GLI2 can mediate these events.

Hedgehog and GLI2 in WM
Several transcription factors play a variety of roles in the biology of WM. Among
them is the transcription factor GLI2. GLI2, GLI family zinc finger 2, is a member of the
GLI family of transcription factors and modulates gene expression directly or through
interaction with other proteins (Ruiz i Altaba et al. 2007). There are three members of
the GLI family of transcription factors (GLI1-3) that act together in response to signaling
from Hedgehog (HH) and other signaling inputs, resulting in the regulation of target
gene expression and ultimately lead to modulated cellular activities. There are two
transmembrane proteins that are involved in and control the HH signaling pathway;
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Patched-1 (PTCH1), which acts as HH signaling receptor, and Smoothened (SMO),
which is the signal transduction component. In the absence of HH ligands, PTCH1
receptor blocks the function of SMO and maintains it in an inactive state. However,
upon binding of any of the three HH ligands (Desert, Indian and Sonic HH) to PTCH1,
the inhibition of SMO by PTCH1 is lifted, thereby allowing SMO to become activate and
initiates and transduces signaling, resulting in the activation of GLI transcription factors
(di Magliano and Hebrok 2003, Ingham and McMahon 2001, Varjosalo and Taipale
2007, Varjosalo and Taipale 2008).
Three GLI genes have been identified: GLI1, GLI2 and GLI3. These possess
distinct repressor and activator functions in HH signaling. As the downstream
component of HH signaling, GLI proteins are post-translationally modified and are
normally suppressed/sequestered in the cytoplasm and prevented from entering the
nucleus. This inactivation is achieved by interaction with cytoplasmic proteins, including
Fused and Suppressor of Fused (Sufu). Activation of the HH signaling pathway initiates
a signaling cascade that leads to cleavage of the GLI proteins, resulting in an Nterminal-truncated activator and C-terminal-truncated repressor fragments, and active
forms of GLI proteins are generated, released from the GLI-Fused-SUFU complex and
translocated into the nucleus. Nuclear GLI proteins proceed along the transcription
factor function and active target gene expression, including PTCH and GLI genes.
Some other target genes are regulated including those that are involved in controlling
cell proliferation, such as cyclin D, cyclin E, Myc and components of the EGF pathway,
in angiogenesis, such as components of the platelet-derived-growth-factor and
vascular-epithelial-growth-factor pathway (di Magliano and Hebrok 2003). Cytokines in
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the BM microenvironment are also targets of GLI and regulate malignant cell growth
and survival (Elsawa et al. 2011a, Jackson et al. 2015, Mauviel et al. 2010, Zhao et al.
2006). HH-GLI signaling pathway is also involved in cancer development. Mutations in
Sonic HH has been reported to cause basal cell carcinomas in mice, suggesting that
HH may have a role in human tumorigenesis (Oro et al. 1997). Constitutively active
mutations of SMO have been found in basal cell carcinoma, and GLI1 was originally
identified in human glioma (Kinzler et al. 1987). Moreover, ectopic expression of
transcription factor GLI1 in the embryonic frog epidermis results in tumor development
and induces basal cell carcinoma formation (Dahmane et al. 1997). Similarly,
overexpression of GLI1 in mice induces basal cell carcinoma as well as other folliclederived neoplasias, such as trichoepitheliomas, cylindromas and trichoblastomas
(Nilsson et al. 2000). In addition, overexpression of GLI2 in the skin also induces basal
cell carcinomas in mice (Grachtchouk et al. 2000).
The regulation and transcriptional role of GLI2 have been widely studied. Studies
on TGF-β show that TGF-β induces the expression of GLI2 in various human cell types,
including normal fibroblasts and keratinocytes, as well as various cancer cell lines. This
induction is rapid, independent of HH signaling and requires a functional SMAD
pathway (Dennler et al. 2007). This finding indicates that GLI2 can be activated without
signaling from HH receptors and identifies TGF-β as potent transcriptional inducer of
GLI2 (Dennler et al. 2007). Interestingly, GLI2 was also found to modulate TGF-β1
expression in CD4+ T cells by regulating the promoter of TGF-β1 (Furler and
Uittenbogaart 2012). In bone marrow stromal cells, GLI2 was found to be activated
through CCR3-PI3K-AKT signaling pathway without signaling from HH (Elsawa et al.
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2011a). In WM B cells, GLI2 was found to regulate IgM secretion via regulation of IL6Ra expression, again in a HH independent mechanism (Jackson et al. 2015). These
studies indicate that GLI2 can be activated even in the absence of HH signaling,
through TGF-β and CCR3. Moreover, GLI2 has also been reported to play a critical role
in maintaining the tumorigenic properties of prostate cancer cells (Thiyagarajan et al.
2007).
In melanoma cell lines, increased GLI2 expression was associated with loss of Ecadherin expression and with an increased capacity to invade Matrigel and form bone
metastases in mice, indicating that GLI2 is directly involved in driving melanoma
invasion and metastasis (Mauviel et al. 2010). The role of GLI2 in the BM
microenvironment has also been investigated. In bone marrow stromal cells, signaling
initiated by CCL5 in the TME leads to up-regulation of Ig production by malignant B
cells. CCL5 promotes IL-6 expression and secretion in stromal cells via GLI2, and IL-6
in turn, induces Ig secretion by malignant B cells (Elsawa et al. 2011a). Work from this
dissertation research identified CD40L as a novel downstream target of GLI2 in bone
marrow stromal cells. Signaling through the CCR3-PI3K-AKT pathway can modulate the
GLI2-CD40L axis, and GLI2 was found to be required for CCR3-PI3K-AKT-mediated
regulation of the CD40L promoter (Han et al. 2017). These studies report a biological
effect of TME-mediated GLI2 on WM cells and reveals the contribution of GLI2 to WM
biology via regulating cytokines in the BM microenvironment, further supporting a role
for GLI2 in promoting WM cell growth, survival as well as IgM production.
Collectively, there is evidence to support a role for targeting the TME as a
therapeutic strategy in cancer. Since the bone marrow microenvironment provides a
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protective role for WM cells, and promotes WM cell activation, growth, survival and IgM
production, targeting BM microenvironment or the cytokines involved in the BM
microenvironment may provide opportunities for therapeutic advances.
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CHAPTER ONE
TARGETING IL-6 RECEPTOR REDUCES IGM LEVELS AND TUMOR GROWTH IN
WALDENSTRÖM MACROGLOBULINEMIA

Introduction

Waldenström macroglobulinemia (WM) is a subtype of non-Hodgkin lymphoma
(NHL) characterized by infiltration of the bone marrow with lymphoplasmacytic cells
(Kapoor et al. 2015). Despite WM being an indolent lymphoma, WM cells secrete very
high levels of a monoclonal immunoglobulin M (IgM) protein, which is associated with
symptoms such as anemia, serum hyperviscosity syndrome and peripheral neuropathy
(Ansell et al. 2010). At initial diagnosis, many WM patients do not require immediately
clinical intervention unless disease symptoms, mostly associated with hyperviscosity
syndrome are evident (Ansell et al. 2010, Gertz 2018a, b). In the past decade, several
significant enhancements were made in our understanding of WM biology. This has led
to the evaluation and introduction of several new therapeutic options for WM patients.
Current therapies used for the treatment of WM patients mainly focus on targeting
cancer cells directly using combination therapies. Rituximab-containing therapies are a
standard of care in the United States. This includes therapies such as R-CHOP
(Cyclophosphamide, doxorubicin, vincristine and prednisone plus rituximab). Ibrutinib, a
BTK inhibitor, is the only FDA approved therapy for WM. However, it is administered
indefinitely and can cause adverse reactions such diarrhea, thrombocytopenia, rash,
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atypical bleeding, among other symptoms (Gertz 2018b). However, despite evidence for
a role of the tumor microenvironment (TME) in promoting WM cell growth, survival and
IgM secretion (Jalali and Ansell 2016), there have been little studies investigating
targeting the TME as a therapeutic strategy for WM patients.
Despite the progress made to understand disease biology, like most other
neoplasms, WM remains an incurable disease and ultimately patients succumb to
disease progression. The TME plays an important role in the development and
progression of WM and has been shown to play a protective role in resistance to
therapy (Jalali and Ansell 2016, Leleu et al. 2007, Roccaro et al. 2010). In fact, the
cross-talk between malignant cells and cells in the TME favors disease progression and
promotes IgM secretion. In previous studies, we and others have shown that IL-6 from
the TME promotes IgM secretion and cell growth via binding to the IL-6R on WM cells
(Elsawa et al. 2011a, Elsawa et al. 2011b, Hatzimichael et al. 2001, Jackson et al.
2015). Therefore, targeting IL-6/IL-6R signaling may provide therapeutic benefit for WM
patients, particularly those with high levels of IgM in their serum.
Tocilizumab/Actemra is an anti-IL-6R antibody, which can competitively block IL6 binding to the IL-6Ra. Tocilizumab has been administered or investigated in several
clinical settings in patients with several inflammatory-mediated diseases including
Castleman’s disease, rheumatoid arthritis, systemic juvenile idiopathic arthritis, crohn’s
disease, giant cell arteritis, systemic sclerosis, systemic lupus erythematosus and
multiple sclerosis (Hunsucker et al. 2011, Tanaka et al. 2011). These studies indicate
that administration of Tocilizumab can be used as a novel therapy to block IL-6 in these
chronic inflammatory conditions and suggest its potential role in other diseases in which
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IL-6 plays a role. Furthermore, several studies have investigated the addition of anti-IL-6
therapy in multiple myeloma (MM) with enhanced results over chemotherapeutic
regimens (Hunsucker et al. 2011, Rossi et al. 2005, Shah et al. 2016). However, despite
investigations of anti-IL-6 therapy in autoimmune and malignant disorders, no studies to
date have investigated its therapeutic efficacy in WM.
In this study, we report the efficacy of targeting the TME with Tocilizumab in a
preclinical mouse model of WM that considers the role of the TME in disease biology.
We show that Tocilizumab reduced tumor growth and IgM secretion and suggest it may
provide therapeutic benefit to WM patients.

Materials and methods
Cells and reagents
The BCWM.1 cells (Ditzel Santos et al. 2007, Drexler et al. 2013) were kindly
provided by Dr. Steve Treon (Dana Farber Cancer Institute, Boston, MA), the RPCIWM1 cells (Chitta et al. 2013, Drexler et al. 2013) were kindly provided by Dr. ChananKhan (Mayo Clinic, Jacksonville, FL) and HS-5 cells were purchased from ATCC
(Manassas, VA). WM cells were maintained in RPMI and HS-5 cells in DMEM, all
supplemented with 10% FBS and antibiotics/antimycotics as previously published
(Elsawa et al. 2011a, Elsawa et al. 2008, Elsawa et al. 2011b, Han et al. 2017, Jackson
et al. 2015).
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Mice
Hairless SCID mice (male; 6-8 weeks old; Charles River, Wilmington, MA) were
purchased and allowed to acclimate for 2 weeks. Mice were then subcutaneously
implanted with BCWM.1 cells (10 x 106) and HS-5 cells (2 x 106) (5:1 ratio) as
previously published (Elsawa et al. 2011a). Mice were cared for and handled in
accordance with institutional and National Institutes of Health guidelines, after obtaining
IACUC approval. Mice were treated with 100 µg/mouse either Tocilizumab or control
antibody (Genentech, South San Francisco, CA) in a total volume of 100 µl injected via
intraperitoneal route every other day for a total of 5 weeks (Figure 1-1A). Tumors were
measured (using digital calipers; Fisher Scientific, Waltham, MA) and mice were
weighed 3 times/week. Upon euthanasia, tumor samples and sera were harvested and
stored for later use.

IgM ELISA
Human IgM in mice sera was quantified using human IgM ELISA (Bethyl
laboratories, Inc., Montgomery, TX) following manufacturer’s recommendations, as
previously published (Elsawa et al. 2011a) using ELISA plates (Nunc Maxisorp, Fisher
Scientific). ELISA plates were developed using the Turbo TMB-ELISA (Fisher Scientific)
and the reaction was stopped by addition of 2N H2SO4. Results were quantified using a
plate reader (Molecular Devices, Palo Alto, CA) and data was analyzed using SoftMax
Pro 7.0.2 software.
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Statistical analysis
The last observed outcome data for actual tumor volume, tumor volume relative
to baseline and mice weights were compared between treatment groups using a
Student’s t-test with the assumption of unequal variance. The mixed effect model with
the assumption of random intercepts and slopes for the trajectory lines for each mouse
were also fitted to compare the slope of the growth of the outcome measures between
treatment groups. The fixed interaction term of the number of days from baseline by
treatment indicator were tested for the difference of two arms. All analysis were
conducted within tumor type (BCWM.1 or RPCI-WM1).

Results
Targeting IL-6/IL-6R signaling in the WM TME does not affect mice survival
Because bone marrow stromal cells in the WM TME are an important source of
IL-6, we subcutaneously implanted hairless SCID mice with BCWM.1 cells or RPCIWM1 cells and HS-5 stromal cells at a ratio of 5:1 onto the right flank of mice. This
allowed us to examine the role of paracrine IL-6 from bone marrow stromal cells, which
have been shown to play an important role in malignant B cells in WM cells (Elsawa et
al. 2011a, Elsawa and Ansell 2009, Elsawa et al. 2011b, Han et al. 2017, Jalali and
Ansell 2016) in vivo. Upon tumor appearance, we treated mice with either Tocilizumab
or IgG control antibody every other day for 5 weeks (Figure 1-1A) and examined the
effect of therapy on mice survival. In accordance with Institutional IACUC, mice were
euthanized when tumors reached 2 cm in any dimension or when tumors became

53

ulcerated. We found that Tocilizumab treatment did not affect overall survival in mice
xenografted with BCWM.1 or RPCI-WM1 and stromal cells (Figure 1-1B).

Targeting IL-6/IL-6R signaling with Tocilizumab reduces tumor growth and IgM
secretion
Tumor growth was monitored and recorded 3 times/week. When we examined
the rate of tumor growth (tumor growth relative to the size of the first recorded tumor),
we found a significant reduction in tumor growth rate in mice implanted with RPCI-WM1
and stromal cells and treated with Tocilizumab (p=0.0394) (Figure 1-2B). Although the
overall tumor growth rate was not statistically significant in mice implanted with
BCWM.1 cells and stromal cells, the rate of tumor growth was slower in Tocilizumab
treated mice (Figure 1-2A). Interestingly, when we examined actual tumor volume and
tumor growth rate in mice implanted with BCWM.1 and stromal cells at day 14 (when all
mice were alive), we found a significant reduction in tumor growth rate (p=0.0306)
(Figure 1-2C). We also found a reduction in the actual tumor volume in this group at
day 14, although this did not reach statistical significance (p=0.057) (Figure 1-2C). This
is consistent with our previous reports on the effect of IL-6 on malignant cell growth in
WM, where IL-6 induced a modest increase in WM cell proliferation in this indolent
lymphoma (Elsawa et al. 2011a, Elsawa et al. 2011b).
The role of IL-6 in normal and malignant B cell biology is well established
(DuVillard et al. 1995, Elsawa et al. 2011b, French et al. 2002, Hatzimichael et al. 2001,
Hirano 1991, Kishimoto 2005). IL-6 has been shown to promote immunoglobulin (Ig)
secretion in normal B cells (Kishimoto 2005) and malignant B cells (DuVillard et al.
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1995, Elsawa et al. 2011b, French et al. 2002, Hatzimichael et al. 2001, Hirano 1991,
Jackson et al. 2015). We have previously shown that IL-6 promotes IgM secretion in
WM (Elsawa et al. 2011a, Elsawa et al. 2011b). Therefore, we examined the effect of
IL-6 therapy on human IgM secretion in mice sera. Consistent with our previous reports,
we found a significant reduction in human IgM secretion in mice sera in groups of mice
xenografted with BCWM.1 cells and stromal cells, treated with Tocilizumab (p=0.0029)
(Figure 1-3). However, in mice xenografted with RPCI-WM1 cells and stromal cells,
there was no reduction in IgM secretion with Tocilizumab treatment (Figure 1-3). The
RPCI-WM1 tumors were significantly larger (928.8 +/- 599.6 mm3 in control mice) than
BCWM.1 xenografted mice (115.1 +/- 73.23 mm3 in control mice) prior to euthanasia of
mice in either group. Furthermore, of the 3 WM cell lines that are currently available,
RPCI-WM1 cells secrete the highest levels of IgM (data not shown).

Targeting IL-6 receptor with Tocilizumab does not induce toxicity
To examine potential therapy-induced toxicities, we monitored the weights of
mice three times/week. Tocilizumab treated mice did not differ from control mice in
weight in RPCI-WM1 xenografted mice (Figure 1-4A). In BCWM.1 xenografted mice,
there was a significant (p=0.005) difference in mice weights between Tocilizumab
treated mice and control mice (Figure 1-4A). However, when we examined individual
mice within each group, the data indicates that control mice consistently increased their
weight, while the majority (7/10 mice) of Tocilizumab-treated mice either maintained
their weight or increased it (Figure 1-4B). Taken together, these results suggest that
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targeting IL-6 in the TME reduced tumor growth rate and IgM secretion while having no
toxic effects on mice.
We performed immunohistochemical staining of tumor biopsies with H&E and
found a similar cellular morphology composed of small round cells in the 2 mice
treatment groups (Figure 1-5). This is consistent with B cell morphology and suggests
growth of WM cells to form these tumors.

Discussion
The role of the bone marrow TME in WM and other B cell malignancies is well
documented (Burger et al. 2009, Burger and Stewart 2009, Elsawa and Ansell 2009, He
et al. 2004, Leleu et al. 2007). Interactions between malignant B cells and stromal cells
in the TME play an essential role in regulating malignant B cell biology including cell
growth, cell survival and Ig secretion (Burger et al. 2009, Elsawa et al. 2011a, Jalali and
Ansell 2016). In previous work, we have shown that IL-6 levels are elevated in WM
patients and IL-6 from human bone marrow stromal cells can promote WM cells growth
and IgM secretion (Elsawa et al. 2011a, Elsawa and Ansell 2009). This finding led us to
investigate the efficacy of blocking IL-6 to block the interaction between the TME and
WM cells. Our results show that targeting IL-6 in the WM TME did not affect the survival
in two WM cell line models investigated (Figure 1-1B). This finding is not surprising, as
IL-6 does not induce apoptosis of WM cells (Elsawa et al. 2011b). Rather, the role of IL6 in WM was shown to promote IgM secretion and WM cell growth (Elsawa et al. 2011a,
Elsawa et al. 2011b). Consistent with this role, we did find a reduction in tumor growth
rate when tumor bearing mice were treated with Tocilizumab (Figure 1-2). These
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results indicate that targeting IL-6 in the TME in WM may slow the rate of tumor growth.
Since WM remains an incurable disease, a reduction in IgM levels may provide a much
needed symptomatic relief for patients. Future studies combining targeting of IL-6 with
therapies that induce apoptosis of WM cells, may prove to be effective; with IL-6 therapy
slowing tumor growth and another therapy targeting the malignant cells. Currently,
Ibrutinib is the only drug approved by the Food and Drug Administration (FDA) for WM
patients. However, several other therapies are used as monotherapies or in
combination and include Bendamustine, Rituximab, Dexamethasone, Fludarabine,
Chlorambucil, Everolimus, among others (Kapoor et al. 2015). An examination of the
role of Tocilizumab therapy in combination with these therapies may allow a dose
reduction in these therapies and therefore alleviate some of the side effects associated
with each therapy.
One of the hallmarks of WM is the overproduction of monoclonal IgM (Elsawa et al.
2011a, Elsawa et al. 2006, Elsawa et al. 2011b, Han et al. 2017, Jackson et al. 2015).
Our results show that tumor-bearing mice treated Tocilizumab had reduced levels of
human IgM secretion in mice serum (Figure 1-3). Interestingly, RPCI-WM1 tumorbearing mice treated with Tocilizumab had similar levels of IgM as control mice. The 2
WM cell lines used in this study are derived from different WM patients (Chitta et al.
2013, Ditzel Santos et al. 2007). Interestingly, RPCI-WM1 cells secrete the highest
levels of IgM among the available WM cell lines (data not shown), raising the possibility
that the rate of increase in IgM levels in patient may correlate with the efficacy of
Tocilizumab monotherapy. Therefore, an examination of the efficacy of IL-6 therapy in
WM patients is necessary to evaluate its effect on IgM levels and tumor growth.
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Taken together, these data suggest that administration of Tocilizumab monotherapy
to tumor bearing mice results in a reduction in tumor burden and IgM secretion, despite
the presence of IL-6 from bone marrow stromal cells in the TME. Therefore,
administration of an anti-IL-6 therapy such as Tocilizumab to WM patients may provide
therapeutic efficacy by targeting the TME to reduce IgM production and slow (Burger et
al. 2009, Burger and Peled 2009, Elsawa and Ansell 2009, He et al. 2004, Leleu et al.
2007) the rate of tumor growth.
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Figure 1- 1. Mouse survival in the presence of Tocilizumab therapy.

59

Figure 1-1: (A) Hairless SCID mice (n=10 mice/group) were subcutaneously injected
with 10 x 106 BCWM.1 or RPCI-WM1 cells + HS-5 stromal cells (5:1 ratio). Upon tumor
appearance (day 7), groups of mice were treated with either Tocilizumab or Control
antibody (IgG) at 100μg/mouse i.p every other day for a total of 5 weeks. (B) Mice were
monitored and survival was reported.
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Figure 1- 2. Targeting the TME with Tocilizumab reduces tumor growth.
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Figure 1-2: (A) Relative tumor growth rate in BCWM.1 (left; n=10/group) and RPCIWM1 (p=0.0394) (right; n=10/group) (both with stromal cells) xenografted mice treated
with either Tocilizumab or IgG control. The Y-axis indicates tumor volume relative to first
recorded tumor size. (B) Tumor volume (left; p=0.057) and relative tumor growth (right,
p=0.0306) on day 14 in mice xenografted with BCWM.1 cells and stromal cells. (C)
Actual tumor volume (left, p=0.057) and tumor growth rate (right, p=0.0306) on day 14
in mice injected with BCMW.1 and stromal cells.
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Figure 1- 3. Tocilizumab reduces human IgM secretion in mice xenografted with
BCWM.1 cells and stromal cells.
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Figure 1-3: Serum was harvested from mice xenografted with BCWM.1 (left; p=0.0029)
and RPCI-WM1 (right) cells upon euthanasia and used to quantify human IgM levels in
mice sera. IgM levels were determined using a human IgM ELISA.
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Figure 1- 4. Tocilizumab is not toxic to mice.
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Figure 1-4: (A) Mice weights were monitored 3x/week and recoded to determine
potential treatment toxicity for BCWM.1 (p=0.005) and RPCI-WM1 xenografted mice.
(B) Individual mice weights on day 9 (first recorded weight) and day 42 (experiment end
point) for mice xenografted with BCWM.1 cells and stromal cells.
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Figure 1- 5. Histology of tumors post euthanasia.
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Figure 1-5: H & E staining for tumors harvested from mice treated with Tocilizumab and
control (BCWM.1 left, RPCI-WM1 right). Tumor samples were harvested and
immediately fixed in 4% formaldehyde. Five µm sections were then stained with H & E
as described in the methods.
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CHAPTER TWO
NOVEL MOLECULAR MECHANISM OF REGULATION OF CD40 LIGAND BY THE
TRANSCRIPTION FACTOR GLI2

Introduction
The tumor microenvironment (TME) plays an integral role in tumor cell biology
and therefore it is difficult to dissociate the role of the TME from cancer cell biology.
Signals from the TME have been shown to promote activation, proliferation, survival and
cancer cell resistance to therapy (Briones et al. 2002, Burger et al. 2009, Cheung and
Van Ness 2001, Elsawa et al. 2011a, Elsawa and Ansell 2009, Elsawa et al. 2006,
Elsawa et al. 2011b, Finger and Giaccia 2010, Inácio Pinto et al. 2015, Kurtova et al.
2009b, Leleu et al. 2007, Moreaux et al. 2004, Pellegrino et al. 2005, Roccaro et al.
2010, Tournilhac et al. 2006). In bone marrow malignancies such as multiple myeloma
(MM) and Waldenström macroglobulinemia (WM), bone marrow stromal cells play an
important role in malignant cell biology by secreting a variety of cytokines that are used
by malignant cells to survive and proliferate (Azab et al. 2012b, Burger et al. 2009,
Burger and Peled 2009, Cheung and Van Ness 2001, Elsawa et al. 2011b, Kurtova et
al. 2009a). Therefore, understanding the regulation of these cytokines in stromal cells is
fundamental for our understanding of the role of the TME in malignant cell biology, and
ultimately allows for the development of targeted therapies toward the TME.
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Among the pathways controlling the bone marrow TME is CD40 signaling. This
pathway is activated by its ligand (CD40L, as known as CD154), a 39 KDa type II
transmembrane protein that belongs to the TNF gene superfamily (Schönbeck et al.
2000). This molecule is preferentially expressed by activated CD4+ T cells and
activated platelets, although it can also be variably expressed by monocytes, NK cells,
B cells, CD8+ T cells, mast cells, basophils and endothelial cells (Fiumara and Younes
2001, Mach et al. 1997, Schönbeck et al. 2000). CD40L can be cleaved from the cell
surface to produce a soluble biologically active form (sCD40L) (Schönbeck et al. 2000).
CD40L binds to its receptor CD40 on the surface of normal and malignant B cells and
triggers a signaling cascade that leads to the activation of various transcription factors
such as AP-1, NFAT and NF-κB (Srahna et al. 2001). In hematological malignancies
such as chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and
Waldenström macroglobulinemia (WM), CD40L/CD40 signaling induces increased
growth and survival of malignant cells (Azab et al. 2012b, Burger and Peled 2009, Clodi
et al. 1998, Fiumara and Younes 2001, Inácio Pinto et al. 2015, Kurtova et al. 2009a,
Mach et al. 1997, Schönbeck et al. 2000, Srahna et al. 2001, Tournilhac et al. 2006).
Therefore, disrupting the CD40L/CD40 pathway may offer therapeutic potential in
malignant diseases. However, the mechanism controlling the regulation of the pathway
remains poorly understood, thus limiting the targeting of this cascade in the clinical
setting.
In this study, we identify CD40L as a novel target gene of the transcription factor
GLI2 in the bone marrow microenvironment. GLI2, is an oncogenic member of the GLI
family of transcription factors (Pasca di Magliano et al. 2006, Rohatgi and Scott 2007,
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Ruiz i Altaba et al. 2007). Overexpression of GLI2 has been reported to play a role in
oncogenic transformation in multiple tissues (Amarsaikhan and Elsawa 2013, Elsawa et
al. 2011a, Furler and Uittenbogaart 2012, Jackson et al. 2015, Javelaud et al. 2011,
Kumar et al. 2015, Takahashi et al. 1995). A screen for cytokines that are differentially
regulated by GLI2 identified CD40L as a GLI2 target gene. Using quantitative RT-PCR
and western blot, we found a strong induction of CD40L expression. We identified 2
candidate GLI binding sites in the promoter region of CD40L. We used a combination of
luciferase and chromatin immunoprecipitation assays to show that GLI2 regulates
CD40L expression by binding to its promoter and modulating its activity. Further
analysis indicated that GLI2-mediated regulation of CD40L occurs downstream of the
CCR3 signaling pathway. GLI2 was found to be required for CCR3-PI3K-AKT mediated
regulation of CD40L. Using stable cell lines with CCR3 or GLI2 knockdown, we confirm
the role of the CCR3-GLI2 signaling axis in the regulation of CD40L. Taken together,
our studies identify a novel mechanism of regulation of CD40L via CCR3-GLI2 signaling
in stromal cells as a novel transcriptional target of GLI2 and increases our
understanding of the repertoire of cytokines that are modulated by this transcription
factor in TME.

Materials and Methods
Cell culture and reagents
The bone marrow stromal cell line HS-5 and mouse embryonic fibroblasts NIH3T3 were purchased from ATCC (Manassas, VA) and maintained in DMEM
supplemented with 10% FBS and penicillin/streptomycin (P/S). L87 and L88 bone
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marrow stromal cells were kindly provided by Dr. Chiara Corsini (European Institute of
Oncology, Milan, Italy) and maintained in RPMI supplemented with 10% FBS and P/S.
The Saka cell line was kindly provided by Dr. David Roodman (University of Pittsburgh,
Pittsburgh, PA), and maintained in MEMα supplemented with 10% FBS and P/S as
previously described (Elsawa et al. 2011a, Takahashi et al. 1995). BCWM.1 (Ditzel
Santos et al. 2007) B cell line was a generous gift from Dr. Steven Treon (Dana Farber
Cancer Institute, Boston, MA), MWCL-1 (Hodge et al. 2011) cells were a kind gift from
Dr. Stephen Ansell (Mayo Clinic, Rochester, MN), and RPCI-WM1 (36) cells were from
Dr. Asher Chanan-Khan (Mayo Clinic, Jacksonville, FL). All B cells were grown in RPMI
1640 with 10% FBS and P/S. The GLI1/GLI2 inhibitor, Gant61, was purchased from
EMD Millipore (Billerica, MA). Antibodies against GLI2 and CD40L for western blot were
both obtained from Abcam (Cambridge, UK). The PI3K inhibitor (LY294002) was
obtained from Selleckchem (Houston, TX).

Plasmid constructs and cell transfections
Short hairpin RNA (shRNA) targeting GLI2 was purchased from Origene
Technologies (Rockville, MD) using plasmid vector backbone pGFP-V-RS. The shRNA
targeting CCR3 was purchased from Santa Cruz Biotechnology (Dallas, TX) as
previously described (Elsawa et al. 2011a). The GLI2 expression construct (in
pCDNA3.1 6XHis) was previously described (Jackson et al. 2015). The CD40L
promoter construct (in pGL3 basic vector), constitutively active (ca) PI3K and AKT,
dominant negative (dn) PI3K and AKT were kindly provided by Dr. Martin FernandezZapico (Mayo Clinic, Rochester, MN). CD40L expression construct was kindly provided
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by Dr. Silvia Bruno (Genoa University, Italy). The dominant active pCS2-MT GLI2 delta
N (ΔN GLI2) plasmid (Roessler et al. 2005) was obtained from Dr. Erich Roessler
through Addgene (plasmid # 17649) (Cambridge, MA).
For transfection experiments, 4×106 cells were electroporated with the indicated
concentrations of plasmid constructs at 250 V for 25 ms and harvested after 48 hours,
unless otherwise noted. For overexpression experiments, 5 μg of expression construct
was used and 10 μg of shRNA was used for knockdown studies. In luciferase
experiments, 2 μg of luciferase reporter construct was used.

RNA Isolation and quantitative PCR (qPCR)
Total RNA was isolated using TRIsure reagent (Bioline, London, UK) following
manufacturer’s recommendations. Reverse transcription reactions were conducted by
Moloney murine leukemia virus (MMLV) reverse transcriptase (Promega, Madison. WI).
Quantitative real-time PCR (qPCR) was conducted using the ViiA 7 real-time PCR
system (Life Technologies, Grand Island, NY). For expression of GLI2, CD40L or CCR3
relative to the expression of the housekeeping gene, GAPDH, the following primers
were used: GAPDH, 5’-CTCGACTTCAACAGCGACA-3’ (forward) and 5GTAGCCAAATTCGTTGTCATACC-3’ (reverse); GLI2, 5’CTCCGAGAAGCAAGAAGCCA-3’ (forward) and 5-GATGCTGCGGCACTCCTT-3’
(reverse); CD40L, 5’-AACATCTGTGTTACAGTGGGCT-3’ (forward) and 5AACGGTCAGCTGTTTCCCAT-3’ (reverse); and CCR3, 5’CTACTCCCACTGCTGCATGA-3’ (forward) and 5’-CTGCTGTGGATGGAGAGACA-3’
(reverse).
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Cytokine arrays
HS-5 stromal cells (4 x 106) were transfected with GLI2 overexpression construct.
After 48 hours, cells were collected, RNA was isolated and reverse transcribed.
Samples were then screened for GLI2 cytokine targets by qPCR using RT2 Profiler
PCR Arrays kit from Qiagen (Hilden, Germany). Samples were analyzed on a Mx3000p
Multiplex Quantitative PCR system (Agilent Technologies, Santa Clara, CA).

Proliferation assay
Cells were serum starved in media with 0.5% FBS and then resuspended in
medium with 0.5% FBS without phenol red at a concentration of 0.25 X 106 cells/mL.
100 μL of cell suspension were plated in triplicate wells of a 96-well plate and an
additional 100 μL of conditioned medium from stromal cells transfected with either
empty vector or ΔN GLI2 expression construct at a final concentration of 50%
conditioned media in a final volume of 200 μL/well After 3 days, 50 μL of XTT working
solution (Trevegin, Gaithersburg, MD) was added to each well and incubated at 37 oC
for 3 hr then analyzed on an Epoch plate reader (Biotek, Venooski, VT).

Coculture experiments
NIH-3T3 cells stably expressing CD40L or wild-type NIH-3T3 cells (0.25 X 106
cells/ml) were irradiated with 10Gy followed by plating 100 μL/well in 96-well plates.
Cells were allowed to adhere overnight followed by removal of media and addition of
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serum-starved B cells (0.25 X 106 cells/ml) in 100 μL/well (ratio of stromal cells: B cells
is 1:1). Cocultures were incubated for an additional 3 days then 50 μL of XTT working
solution (Trevegin, Gaithersburg, MD) was added to each well and incubated at 37oC
for 3 hr then analyzed on an Epoch plate reader (Biotek, Venooski, VT).

Enzyme-linked immunosorbent assay (ELISA)
ELISA plates (Nunc maxisorp; Nalgene Nunc International, Rochester, NY) were
used to quantify soluble CD40L (sCD40L) levels. Human CD40L ELISA (Peprotech,
Rocky Hill, NJ) was used following manufacturer recommendations. Reactions were
stopped by the addition of 1N H2SO4 and the data was analyzed using an Epoch plate
reader (BioTek).

Immunoblotting
Total protein lysate was collected from stromal cell lines and protein
concentration was determined by a BCA protein assay kit from Thermo Fisher Scientific
(Waltham, MA). Protein was loaded into each well of a 7.5% SDS protein gel and a
semidry transfer system (Bio-Rad, Hercules, CA) was used to transfer proteins to a
nitrocellulose membrane. Ab specific for GLI2, CD40L or β-actin was used to detect
protein. Densitometry was performed using ImageJ software, normalized to control and
presented as an average of 3 independent experiments.
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Luciferase reporter assay
Cells (2×106) were transfected as described and plated in triplicate wells in 24well plates. Following 2-day incubation with media containing 10% FBS, cells were
harvested and assayed for luciferase activity following manufacturer’s protocol
(Promega Corporation, Madison, WI). To control for variations in transfection efficiency,
luciferase readings were normalized to total protein for each sample using a BCA
protein assay kit (ThermoFisher Scietific). Relative luciferase units (RLU) represents
luciferase readouts/protein concentration relative to control samples in each experiment.

Chromatin immunoprecipitation (ChIP) assay
Chromatin immunoprecipitation was conducted as previously described(Lo Re et
al. 2012). Briefly, chromatin was digested with micrococcal nuclease (2 gel units/ul; New
England Biolabs, Ipswich, MA) for 20 min at 37 oC. Chromatin was further sheared by
sonication for 5 cycles of 1 min on/1 min off at 4 oC and 5 cycles of 30s on/30s off at 4
oC

(Bioruptor; Diagenode, Denville, NJ). Aliquots of sheared chromatin were subjected

to immunoprecipitation using an anti-GLI2 Ab (Novus Biologicals) or normal rabbit IgG
(EMD Millipore). qPCR of the ChIP products and genomic input DNA was conducted
using specific designed primers that amplify an area of the CD40L promoter containing
GLI binding sites. The sequences of primers are as following: Binding site 1 (BS1), 5’GCCTCTGACTTGACTGATCAAAG-3’ (forward) and 5’-CCTGCTTTCTTCCCCTCCC-3’
(reverse); Binding site 2 (BS2), 5’-GTGGCCACTTTGACAGTCTTC-3’ (forward) and 5’GCCGCAGATCGGGGAGAAG-3’ (reverse). Quantitative PCR was performed using
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SYBR Green at 65 oC in triplicate for each sample or control, and results are presented
as a percentage relative to input.

Mutations of GLI binding site
Mutations of GLI binding site in CD40L promoter was performed using
QuikChange II XL Site-directed mutagenesis kit (Agilent Technologies, Santa Clara,
CA) following manufacturer’s recommendations. GLI2 binding site 1 (BS1) sequence
from -1482 to -1478 bp was changed from CCACC to AAAAA using the following
primers: 5’GTAGCTTTTCACTACATCTGCCAAGTATTTTTCTTCGATGCACGTGATGAACTTTGA
TC-3’ (sense) and 5’GATCAAAGTTCATCACGTGCATCGAAGAAAAATACTTGGCAGATGTAGTGAAAAGC
TAC-3’ (antisense). Mutated plasmid was verified by sequencing.

Flow cytometry
Fluorochrome-conjugated antibodies used for flow cytometry were obtained from
BD Biosciences. To confirm/compare CD40L expression on wild-type or NIH-3T3 cells
stably expressing CD40L, 0.5*106 cells were stained with CD40L-APC or isotype control
for 20 min followed by washing with FACS buffer and analysis on a FACS Caibur.
To determine B cell activation in response to NIH-3T3s stably expressing CD40L,
serum starved B cells were co-cultured with NIH-3T3 cells for 15 minutes then collected
in FACS tubes. Cells were then permeabilized and stained with the BD
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Cytofix/Cytoperm Plus kit (BD Biosciences 555028) according to manufacturer
recommendations with some modifications. Briefly, cells were spun down and
resuspended in 100 µl of Fix/Perm solution and incubated at 4°C for 30 min. Cells were
then washed twice with Fix/Perm Wash Buffer and resuspended in 50 ul Fix/Perm
solution. Four µg of phosphor-Erk-PE (pErk-PE) antibody or PE-conjugated Isotype
control were added and the tubes were incubated at 4°C for 30 min. Cells were washed
twice with Fix/Perm Wash buffer and resuspended in 50 µl Fix/Perm solution. Cells
were resuspended in 500 µl FACS Buffer and analyzed via Flow-Cytometry. Cells were
analyzed on a FACSCalibur instrument and analyzed using FlowJo software with gating
on viable cell populations.

Statistical analysis
A two-tailed t test was used to determine statistical significance between two sets
or ANOVA for more than two sets of data. A p value <0.05 was considered significant.
Statistical analysis was carried out using GraphPad Prism software.

Results
Screening for novel GLI2 target cytokines identifies CD40L as a candidate GLI2
target gene
We hypothesized that GLI2 can target cytokine genes and modulate their
expression. To address this hypothesis, we screened for cytokines that are important in
the bone marrow tumor microenvironment that are potentially regulated by GLI2. We
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identified several cytokine genes to be differentially regulated by this transcription factor
(Figure 2-1A). Among those genes is the cytokine CD40L. Because CD40L plays a role
in malignant B cell biology (Burger and Gandhi 2009, Fiumara and Younes 2001,
Tournilhac et al. 2006), we co-cultured B cell lines from Waldenström
macroglobulinemia (WM) with stromal cells stably expressing CD40L (Figure 2-1B) and
found an increase in Erk phosphorylation (Figure 2-1C), indicating an increase in
malignant B cell activation. Furthermore, coculture of CD40L-expressing stromal cells
with WM cells induced an increase in WM cell proliferation (Figure 2-1D), further
confirming the importance of the CD40L/CD40 signaling axis in WM B cell lines and WM
biology.

GLI2 regulates the expression of CD40L
To validate cytokine array data, we overexpressed GLI2 in several bone marrowderived stromal cell lines (HS-5, L87, L88 and Saka) and determined the effect on
CD40L mRNA expression by quantitative PCR. Overexpression of GLI2 resulted in a
significant increase in CD40L expression (Figure 2-2A). This also resulted in increased
CD40L protein by western blot (Figure 2-2B). Using RNAi to target GLI2, we found a
significant reduction in CD40L mRNA expression in Saka and L88 cells (Figure 2-2C).
This reduction in CD40L gene expression also resulted in reduced CD40L protein
expression in these stromal cells (which expressed higher levels of CD40L under basal
conditions) in the presence of GLI2 knockdown (Figure 2-2D). The effect of GLI2
knockdown on CD40L expression was partially rescued using RNAi-resistant GLI2
cDNA (Figure 2-2E).
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CD40L can be cleaved from the cell surface to produce a soluble form (sCD40L)
(Schönbeck et al. 2000). Using a dominant active GLI2 cDNA that lacks an N-terminal
repressor domain (ΔN GLI2), we found an increase in sCD40L by ELISA compared with
cells transfected with empty vector (Figure 2-2F). Using supernatant from 2-day
cultures of ΔN GLI2 transfected cells (ΔN GLI2 conditioned media), we found a
significant increase in BCWM.1 and MWCL-1 cell proliferation (p<0.0001) compared to
cells cultured with supernatant from cells transfected with empty vector (Figure 2-2G).
Although this increase in proliferation was modest (12% in BCWM.1 and 13% in MWCL1 cells), this may have biological implications for an indolent lymphoma such as WM
(2005, Dimopoulos and Anagnostopoulos 2005, Fonseca and Hayman 2007, Ghobrial
et al. 2003). Taken together, our data indicate that the transcription factor GLI2
regulates CD40L mRNA and protein expression.

GLI2 directly binds and regulates the CD40L promoter
Bioinformatic analysis of the CD40L promoter region (~ 2000 bp) identified 2
candidate GLI2 binding sites (BS1 and BS2) (Figure 2-3A). To characterize the role of
GLI2 in modulating the CD40L promoter, we utilized a combination of luciferase reporter
and chromatin immunoprecipitation (ChIP) assays. We found that GLI2 overexpression
induces CD40L promoter activity in stromal cells (Figure 2-3B). Conversely, GLI2
knockdown using shRNA targeting GLI2 results in significantly reduced CD40L
promoter activity (Figure 2-3C).
Using ChIP assay, we confirmed that endogenous GLI2 binds to the distal GLI
binding region of the CD40L promoter (BS1) from -1524 to -1397 using qPCR (Figure
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2-3D). To demonstrate the specificity of GLI2 binding to BS1 on the CD40L promoter,
we performed luciferase assay using stromal cells transfected with WT CD40L promoter
sequence or mutant version of this plasmid lacking the GLI2 binding sequence. We
found that GLI2 was not able to increase luciferase activity of the mutant CD40L
promoter although it did increase WT CD40L promoter (Figure 2-4A). Next, we found
that binding of GLI2 to the CD40L promoter was reduced in stromal cells treated with
the GLI inhibitor Gant61 (Figure 2-4B). Treatment of stromal cells with Gant61 also
resulted in a reduction in CD40L mRNA expression (Figure 2-4C). Finally, using HS-5
cells stably transduced with retrovirus containing either shScr or shGLI2 also confirmed
that this binding of GLI2 to CD40L promoter is reduced with GLI2 knockdown (Figure 24D). Together, these results identify CD40L as a novel direct target of the GLI2
transcription factor and for the first time provide evidence for a potential role of GLI2 in
the regulation of this signaling cascade.

CCR3-PI3K-AKT signaling modulates GLI2-CD40L axis
We have previously identified the CCR3-PI3K-AKT signaling pathway as a
regulator of GLI2(Elsawa et al. 2011a). Therefore, to define a potential mechanism
driving this novel GLI2-CD40L axis we examined the role of the CCR3-PI3K-AKT
signaling pathway on the regulation of CD40L. We utilized luciferase reporter and
expression assays to investigate the role of this signaling axis on CD40L. We found that
overexpression of CCR3 increased the mRNA expression of CD40L (Figure 2-5A).
Furthermore, using constitutively active PI3K and AKT mutants, we found an increase in
the expression of CD40L mRNA (Figure 2-5B). Overexpression of CCR3 also resulted
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in an increased in CD40L promoter activity (Figure 2-5C). Conversely, CCR3
knockdown using shRNA results in a reduction in CD40L promoter activity (Figure 25D). Furthermore, we found that constitutively active PI3K (Figure 2-5E) and AKT
(Figure 2-5F) increased CD40L promoter activity and dominant negative forms of PI3K
and AKT that antagonize this pathway reduced CD40L promoter activity (Figure 2-5G).
To confirm the role of PI3K/AKT, we treated stromal cells with the PI3K inhibitor
(LY294002) and examined the downstream effect on CD40L expression. Similar to
results obtained with genetic inhibition of PI3K/AKT, stromal cells treated with the
pharmacological inhibitor of PI3K had a significant reduction in CD40L protein
expression (Figure 2-5H). Finally, in the absence of GLI2, constitutively active AKT was
not able to increase CD40L promoter activity to the extent that it does in the presence of
an intact GLI2 (Figure 2-5I). Taken together, this data demonstrates that the CCR3PI3K-AKT signaling pathway can modulate CD40L expression and promoter activity and
this regulation of CD40L requires an intact GLI2.

CCR3-GLI2-CD40L axis is important in the TME
To validate the role of GLI2 in the regulation of CD40L, we used stromal cells
with stable GLI2 knockdown by retroviral transduction using 2 different shRNAs
targeting GLI2 and found a significant reduction in CD40L expression by qPCR (Figure
2-6A). We also generated stromal cells with stable CCR3 knockdown and found a
reduction in CD40L expression (Figure 2-6B). This reduction in CD40L expression as a
result of CCR3 knockdown was rescued by the introduction of GLI2 cDNA (Figure 26B) downstream of CCR3 signaling. Taken together, these results confirm the role of
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CCR3-GLI2 signaling axis in regulating CD40L expression in the TME and that GLI2
can rescue the effect of CCR3 knockdown on CD40L expression (Figure 2-6A-C).

Discussion
Previous evidence has shown that the bone marrow tumor microenvironment is
critical for the growth and persistence of malignant B cells (Burger et al. 2009). The
interactions between tumor cells and their surrounding cells are essential for malignant
cell biology (Burger et al. 2009, Podar et al. 2008). Our findings presented here have
identified CD40L as a direct transcriptional target gene of GLI2 in stromal cells (Figures
2-2 and 3). Several studies have focus on the role of GLI proteins as the mediators of
Hedgehog signaling pathway (Amakye et al. 2013, Bar et al. 2007, Dierks et al. 2008,
Fernandes et al. 2009, Liu et al. 2006, Varnat et al. 2009). GLI2, one of the transcription
factors from the GLI family, known as the effector of the Hedgehog signaling pathway,
plays a major rule during cell development (Ruiz i Altaba et al. 2007). Here, we focused
our studies on the molecular mechanism of cytokine regulation by the oncogenic
transcription factor GLI2. The results from our initial screening of cytokines potentially
modulated by GLI2 identified several cytokines that are differentially regulated by GLI2
(Figure 2-1). Among those, CD40L was identified as a new novel GLI2 target gene
(Figure 2-1). CD40L is an important cytokine that has been shown to play an important
role during normal B cell responses where it regulates B cell growth, survival, antibody
secretion as well as class switch recombination (CSR) (Wykes 2003). In addition to its
role in normal B cell functions, it has also been shown to modulate malignant B cells
(Burger and Gandhi 2009, Fiumara and Younes 2001, Tournilhac et al. 2006).
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Therefore, understanding the mechanism of its regulation is important to further our
understanding of normal and malignant B cells responses. We found that the oncogenic
transcription factor, GLI2, induces the expression of CD40L in stromal cells (Figure 22). We also show that GLI2 induces an increase in sCD40L and conditioned media from
ΔN GLI2 transfected stromal cells induced an increase in WM cell proliferation (Figure
2-2F and G). Because the increase in proliferation was modest (12-13%), this did not
allow us to observe a statistical difference in WM cell proliferation in the presence of
CD40L blocking antibodies, although the trend was consistent with at least a partial role
for sCD40L (data not shown). This raises the possibility that in addition to sCD40L,
other soluble mediators regulated by GLI2 may contribute to the increase in WM cell
proliferation. A comprehensive understanding of GLI2 target genes is likely to shed light
onto these mechanisms. Moreover, we found that GLI2 modulates CD40L expression
by directly binding to its promoter (Figures 2-3 & 4). Our group has shown that GLI2
can directly target the IL-6 promoter in bone marrow stromal cells and lead to increased
IL-6 expression and secretion (Elsawa et al. 2011a). We also demonstrated a direct role
for GLI2 in regulating IgM secretion by WM cells (Jackson et al. 2015). Therefore, this
study identifies CD40L as a novel GLI2 target gene and suggests a novel mechanism
by which GLI2 modulates malignant B cell biology via modulation of the TME.
Furthermore, we increase our understanding of the repertoire of cytokines that are
regulated by this transcription factor.
Our data identified CD40L as a novel direct target of the GLI2 transcription factor in
human bone marrow stromal cells (Figures 2-1, 2 and 3). Previous studies have shown
that CD40L expression on mast cells in the TME promotes CD40 signaling on primary
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WM B cells (Tournilhac et al. 2006). Our data support these studies showing GLI2mediated CD40L increases WM B cell activation (as evidenced by Erk phosphorylation)
(Figure 2-1C) and ultimately increased malignant B cell proliferation (Figure 2-1D)
upon co-culture with stromal cells stably expressing CD40L. A role for CD40L has been
described in mantle cell lymphoma (MCL) where CD40L promotes activation and
proliferation of MCL cells (Andersen et al. 2000). Similarly, a role for CD40L/CD40
signaling has been described in Hodgkin lymphoma, B cell lymphoma, chronic
lymphocytic leukemia and other hematological neoplasms (Aldinucci et al. 2012, Burger
and Gandhi 2009, Fiumara and Younes 2001, Jin et al. 2004, Schattner 2000, Tong et
al. 2000, Tournilhac et al. 2006, Tsirakis et al. 2012, Voorzanger-Rousselot et al. 1998,
Younes 2001). Despite the importance of CD40L-CD40 signaling in normal and
malignant B cells, little is known about the mechanisms that regulate CD40L
expression. The identification of GLI2 as a regulator of CD40L promoter promotes our
understanding of the regulation of this important cytokine.
The identification of GLI2 as a regulator of CD40L promoter promotes our
understanding of the regulation of this important cytokine. In human T cells, several
transcription factors including AP-1, NF-AT and NF-κB have been shown to modulate
CD40L (Srahna et al. 2001). These transcription factors regulate a region closer to the
transcription start site. The region containing the GLI2 binding site (BS1; -1478) is
located further upstream from the regulatory regions of these transcription factors
(Figure 2-3A). It will be interesting in future studies to address whether GLI2 in concert
with AP-1, NF-AT and NF-κB regulates CD40L expression.
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Previous studies have shown that GLI2 can modulate the expression of TGF-β
(Furler and Uittenbogaart 2012). Furthermore, we have shown that GLI2 modulates the
expression and secretion of IL-6 and IL-6R (Elsawa et al. 2011a, Jackson et al. 2015).
Here, we identify CD40L as a novel GLI2 target genes, therefore increasing our
knowledge of the array of cytokine genes regulated by this transcription factor and
further supporting a role for GLI2 in the regulation of inflammation. Furthermore, this
regulation occurs downstream of CCR3-PI3K-AKT signaling in stromal cells.
In summary, our studies demonstrate a novel role for GLI2 in promoting
malignant B cell activation and proliferation via regulation of CD40L expression in the
TME and signaling through the CCR3-PI3K-AKT pathway can modulate CD40L
expression and promoter activity and this regulation requires an intact GLI2 (Figure 26C). These studies for the first time provide evidence for the molecular mechanism of
GLI2 regulating CD40L expression in human bone marrow stromal cells. Further
investigation of the GLI2-CD40L axis has great potential in increasing our
understanding of the mechanisms of GLI2 regulating cytokines in the TME.
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Figure 2- 1. GLI2 modulates cytokines genes.
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Figure 2-1: (A) HS-5 stromal cells (4*106) were transfected with either empty vector
(Ctrl) or GLI2 expression construct (GLI2). After 48hours, cells were collected and
followed by RNA extraction to determine gene expression by using PRT-PCR arrays as
indicated in methods. (B) FACS analysis showing the expression of CD40L on NIH-3T3
cells stably transfected with human CD40L expression construct compared with wild
type NIH-3T3. (C) NIH-3T3 cells stably expressing CD40L (0.5*106 cells/well) were
allowed to adhere overnight in 6-well plates. Serum-starved malignant B cells
(BCWM.1, MWCL-1 and RPCI-WM1) were then added (1:1 ratio) and incubated for 15
minutes. Non-adherent B cells were then collected and used to determine the level of
ERK phosphorylation by FACS. (D) NIH-3T3 cells were irradiated with 10 Gy,
resuspended at 0.25*106 cells/ml, and 100 ul were plated in 96-well plates and allowed
to adhere overnight. Serum-starved B cells were then added at a ratio of 1:1 were
added to NIH-3T3 cell cultures and incubated at 37℃. After 3 days, cell proliferation was
determined by XTT assay as described in the methods. This experiment was repeated
3X and the data are presented as an average of 3 independent experiments +/- SEM.
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Figure 2- 2. GLI2 induces CD40L expression.
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Figure 2-2: (A) Stromal Cells (4*106) were transfected with either empty vector (Ctrl) or
GLI2 expression construct (GLI2) for 2 days followed by RNA extraction for use to
determine gene expression by qPCR as indicated in methods. (B) Western blot for
CD40L protein in HS-5 and Saka cells transfected with either empty vector (Ctrl) or
GLI2 expression construct (GLI2) for 2 days. (C) qPCR for GLI2 and CD40L using Saka
cells (left) and L88 cells (right) transfected with shScr or shGLI2. (D) L88 and Saka
stromal cells were transfected with shRNA targeting GLI2 (shGLI2) or scrambled control
(shScr). After 2 days, cells were lysed and used to determined protein expression by
western blot. (E) Relative expression of CD40L in L88 stromal cells transfected with
either Ctrl or RNAi-resistant GLI2 cDNA (GLI2) in the presence of either shScr or
shGLI2. Gene expression was determined by qPCR. (F) L88 cells (4*10 6) were
transfected with a dominant active form of GLI2 (ΔN GLI2) or empty vector (Ctrl). After 2
days, supernatants were harvested and used to determine soluble CD40L (sCD40L)
levels by ELISA. (G) Supernatants (50%) from L88 cells transfected with Ctrl or ΔN
GLI2 were used to culture B cells for 3 days followed by determination of cell
proliferation by XTT assay. Each experiment was repeated at least 3 times and bars
represent the mean ± S.E. of triplicate experimental wells.
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Figure 2- 3. GLI2 binds and modulates CD40L promoter.
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Figure 2-3: (A) Bioinformatics analysis of the CD40L promoter identified candidate GLI
(G) binding sites. Gray lines represent amplicons for the primer sets used that span the
GLI binding sites. Forward and reverse primer start sequences are indicated. TSS,
transcription start site. (B) Relative changes in luciferase activity in stromal cells
transfected with CD40L promoter-luciferase reporter and with either empty vector (Ctrl)
or GLI2 expression construct. Cells were harvested after 2 days and changes in
luciferase activity were assayed as described in methods. (C) Relative luciferase activity
in stromal cells transfected with CD40L promoter-luciferase reporter and with either
shScr or shGLI2. Cells were harvested after 2 days and changes in luciferase activity
were assayed. (D) Chromatin immunoprecipitation (ChIP) assay was performed on
lysates from stromal cells using antibodies specific for GLI2 or an IgG isotype control.
Quantitative PCR was performed using primers indicated above for 2 candidate GLI
binding sites.
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Figure 2- 4. CD40L promoter activity with mutated GLI2 binding site and GLI2
inhibition.
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Figure 2-4: (A) Relative changes in luciferase activity in Saka stromal cells transfected
with either wild-type (wt) CD40L promoter-luciferase reporter or CD40L promoter with
mutated BS1 (mut) and with either empty vector (Ctrl) or GLI2 expression construct.
Cells were harvested after 2 days and changes in luciferase activity were assayed as
described in methods. (B) A ChIP assay was performed on L88 cell lysates from cells
treated with either 20 μM GANT61 or DMSO control for 24 hours. qPCR was performed
to determine the effect of treatment on GLI2 binding to the CD40L promoter. (C) HS-5
cells were treated with either 20 μM GANT61 or DMSO control for 24 hours. Cells were
harvested and followed by RNA extraction for use to determine CD40L gene expression
effected by GLI inhibitor GANT61 using qPCR. (D) A ChIP assay was performed on HS5 stromal cells stably transduced with retrovirus containing either shScr or shGLI2.
qPCR was performed to determine the binding of GLI2 to the CD40L promoter. Each
experiment was repeated at least 3 times and Bars represent the mean ± S.E. of
triplicate experimental wells.
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Figure 2- 5. CCR3-PI3K signaling modulates CD40L.
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Figure 2-5: (A) Stromal cells were transfected with a CCR3 expression construct or
empty vector (Ctrl). After 48 hours, RNA was isolated and used to determine CD40L
expression by qPCR. (B) L88 cells were transfected with a constitutively active PI3K
construct (caPI3K), a constitutively active AKT construct (Gruber Filbin et al.), or empty
vector (Ctrl). After 48 hours, RNA was isolated and used to determine CD40L
expression by qPCR. (C-D) Relative luciferase activity in stromal cells transfected with
CD40L promoter-luciferase reporter and either CCR3 expression construct or empty
vector (Ctrl) or shScr or shCCR3. Cells were harvested after 2 days and changes in
luciferase activity were assayed. (E-F) Relative luciferase activity in stromal cells
transfected with CD40L promoter-luciferase reporter and caPI3K, caAKT or empty
vector (Ctrl). Cells were harvested after 2 days and changes in luciferase activity were
assayed. (G) Relative luciferase activity in HS-5 cells transfected with CD40L promoterluciferase reporter and dominant negative PI3K (dnPI3K), dominant negative AKT
(dnAKT) or empty vector for 2 days. Cells were harvested and changes in luciferase
activity were assayed. (H) HS-5 stromal cells were treated with the PI3K inhibitor
(LY294002) or DMSO (Ctrl) for 24 hr followed by immunoblotting to determine CD40L
protein levels. Graph represents densitometry on analyzed immunoblotting images from
3 independent experiments showing a reduction in CD40L protein expression. (I)
Relative luciferase activity in HS-5 cells transfected with CD40L promoter-luciferase
reporter and caAKT or empty vector in the presence of absence of GLI2 (shGLI2). Cells
were harvested after 2 days and changes in luciferase activity were assayed. Each
experiment was repeated at least 3 times and Bars represent the mean ± S.E. of
triplicate experimental wells.
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Figure 2- 6. CCR3 modulates GLI2-CD40L axis in the TME.
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Figure 2-6: (A) Relative changes in GLI2 and CD40L mRNA expression in L88 stromal
cells stably transduced with retrovirus containing either shScr or 2 different shRNA
targeting GLI2 [shGLI2(In et al.) and shGLI2(In et al.)]. RNA was extracted from 10*106
cells and used to determine gene expression by qPCR. (B) Relative changes in CD40L
gene expression in L88 stromal cells stably transfected with either shScr or shCCR3.
Stable cells (4*106 cells) were transfected with either GLI2 cDNA or empty vector. After
2 days, cells were collected and followed by RNA extraction to determine gene
expression by qPCR. (C) Model of CCR3-GLI2-CD40L signaling axis in stromal cells.
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CHAPTER THREE
IDENTIFICATION OF NOVEL GLI2 TRAGET GENES IN HUMAN BONE MARROW
STROMAL CELLS

Introduction
GLI2, GLI family zinc finger 2, is a member of the GLI family of transcription
factors that modulates gene expression directly or indirectly through interaction with
other proteins (Ruiz i Altaba et al. 2007). GLI2, along with two other members of the GLI
family of transcription factors (GLI1 and GLI3), act together in response to signaling
from the Hedgehog (HH) receptor and other signaling inputs, resulting in the regulation
of target gene expression. This ultimately leads to modulated cellular and biological
functions. Subsequent studies have shown that GLI2 can be activated in the absence of
signaling from HH suggested that other signaling pathways may modulate GLI activity.
Indeed, TGF-β has been reported as potent transcriptional inducer of GLI2 and can
activate GLI2 without signaling from HH receptors (Dennler et al. 2007). In bone marrow
stromal cells, GLI2 was found to be activated through CCR3-PI3K-AKT signaling
pathway without signaling from HH (Elsawa et al. 2011a).
The regulation and transcriptional role of GLI2 have been widely studied. GLI2
was found to modulate TGF-β1 expression in CD4+ T cells by regulating the promoter
of TGF-β1 (Furler and Uittenbogaart 2012). In WM B cells, GLI2 was found to regulate
IgM secretion via regulation of IL-6Ra expression, again in a HH independent
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mechanism (Jackson et al. 2015). In melanoma cell lines, increased GLI2 expression
was associated with loss of E-cadherin expression and with an increased invasion and
metastases capacity (Mauviel et al. 2010). In a model of the TME using bone marrow
stromal cells, CCL5/CCR3 signaling in the TME modulates Ig secretion by malignant B
cells. CCL5 promotes IL-6 expression and secretion in stromal cells via GLI2, and IL-6
in turn, induces Ig secretion by malignant B cells (Elsawa et al. 2011a). Work from this
dissertation research identified CD40L as a novel downstream target of GLI2 in bone
marrow stromal cells. Signaling through the CCR3-PI3K-AKT pathway was found to
modulate the GLI2-CD40L axis, and GLI2 was found to be required for CCR3-PI3KAKT-mediated regulation of the CD40L promoter. These studies report a biological role
for GLI2 in the TME and reveals a novel contribution of GLI2 to WM biology via
regulating cytokines in the BM microenvironment.
These studies also raise the possibility that GLI2 may modulate other genes in
the TME that are important in cancer cell biology. Therefore, understanding the genes
that are regulated by GLI2 will be important to enrich our understanding of the role of
GLI2 in regulating inflammation in the TME.
RNA-sequencing (RNA-seq), also known as whole transcriptome shotgun
sequencing, uses next-generation sequencing (deep sequencing) to reveal the
presence and quantity of RNA in a biological sample (Chu and Corey 2012, Wang et al.
2009). Compared to previous Sanger sequencing- and microarray-based methods,
RNA-Seq provides a better resolution to study the nature of the transcriptome and can
be used to investigate polyadenylated message RNA (mRNA) transcripts. In addition,
RNA-Seq can be applied to investigate different populations of RNA, including total
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RNA, pre-mRNA, and noncoding RNA, such as microRNA and long non-coding RNA
(lncRNA), as well as ribosomal profiling (Ingolia et al. 2012, Kukurba and Montgomery
2015). Maher et al employed long and short read transcriptome sequencing to discover
novel gene fusions in cancer cells and established a robust pipeline for the discovery of
novel gene chimeras (Maher et al. 2009).
Here, we knockdown GLI2 using shRNA in human bone marrow stromal cells
and used these RNA samples to perform RNA-Seq to identify potential target genes of
GLI2 for future investigation. These studies will enrich our understanding the role of
GLI2 in regulating inflammation in the TME.

Materials and Methods
Cell culture and reagents
The bone marrow stromal cell line L88 was kindly provided by Dr. Chiara Corsini
(European Institute of Oncology, Milan, Italy) and HS-5 cells were purchased froma
ATCC (Manassas, VA). L88 cells were maintained in RPMI and HS-5 cells in DMEM, all
supplemented with 10% FBS and antibiotics/antimycotics as previously published (8-10,
17, 29 IL-6 paper).

Plasmid constructs and cells transfections
Short hairpin RNA (shRNA) targeting GLI2 was purchased from Origene
Technologies (Rockville, MD) using plasmid vector backbone pGFP-V-RS.
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For transfection experiments, 4×106 cells were electroporated with the indicated
concentrations of plasmid constructs at 250 V for 25 ms and harvested after 48 hours,
unless otherwise noted. 10 μg of shRNA was used for knockdown studies.

RNA Isolation and quantitative PCR (qPCR)
Total RNA was isolated using TRIsure reagent (Bioline, London, UK) following
manufacturer’s recommendations. Reverse transcription reactions were conducted by
Moloney murine leukemia virus (MMLV) reverse transcriptase (Promega, Madison. WI).
Quantitative real-time PCR (qPCR) was conducted using the ViiA 7 real-time PCR
system (Life Technologies, Grand Island, NY). For expression of GLI2 relative to the
expression of the housekeeping gene, GAPDH, the following primers were used:
GAPDH, 5’-CTCGACTTCAACAGCGACA-3’ (forward) and 5GTAGCCAAATTCGTTGTCATACC-3’ (reverse); GLI2, 5’CTCCGAGAAGCAAGAAGCCA-3’ (forward) and 5-GATGCTGCGGCACTCCTT-3’
(reverse).

RNA-Seq
RNA-seq was performed at the Hubbard Center for Genome Studies at the
University of New Hampshire under the supervision from Dr. Kelley Thomas.

Data analysis
Bioinformatic analysis of RNA-seq data was performed by Dr. Christopher Pin at
the University of Western Ontario, Canada.
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Results
GLI2 knockdown in HS-5 and L88 cells
To investigate the genes that are potentially regulated by GLI2, we performed
GLI2 knock down by shRNA targeting GLI2 in HS-5 and L88 bone marrow stromal cells.
Reverse transcription quantitative real-time PCR (qPCR) was used to confirm the
knockdown of GLI2 in our samples prior to RNA-seq experiments. Indeed, qPCR results
confirmed that GLI2 was effectively knocked down in HS-5 (Figure 3-1) and L88
(Figure 3-2) cells. We performed 4 individual experiments and found a significant
reduction in GLI2 expression (at least 50%) compared to scrambled control in both cell
lines tested.

RNA sequencing
At least 2.5 µg of RNA from each sample was used for RNA sequencing.
Because of our interest in understanding the cytokines that are regulated by GLI2, we
identified the top 10 genes that are positively regulated by GLI2. This identified genes
with a reduction in gene expression in the absence of GLI2 (GLI2 knockdown). Our data
using HS-5 cells yielded fewer reads than anticipated. These samples will be repeated
in future studies. However, in L88 cells, we identified over 200 genes that are positively
regulated by GLI2. Of those genes, we show the top 10 genes identified by the
statistical analysis here (Figure 3-3), including Cep170, AGL, VGLL3, KIAA1109,
AKAP11, ETNK1, PRUNE2, IL6ST and MIB1. These genes encode different molecules
which are involved in various cellular activities, such as centrosomal protein 170 kDa
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(Cep170; involved in mitosis); the glycogen debranching enzyme (AGL; involved in the
breakdown of glycogen); transcription factor vestigial-like 3 (VGLL3; targets genes that
have a strong association with multiple autoimmune diseases); KIAA1109 encoded
protein (thought to be involved in the regulation of epithelial growth and differentiation);
AKAP11 (encodes A-kinase anchor protein 11 which belongs to the group of proteins
which binding to the regulatory subunit of protein kinase A); Ethanolamine kinase 1 (a
kinase encoded by ETNK1; involved in the first step of phosphatidylethanolamine
synthesis); PRUNE2 (encodes prune homolog 2 with BCH domain; belongs to an
interacting protein family whose members play roles in many cellular processes
including apoptosis, cell transformation, and synaptic function); IL6ST (gp130; the
interleukin 6 receptor signal transduction subunit that is shared by many cytokines
including IL-6); and MIB1 (encodes the mind bomb E3 ubiquitin protein ligase1; a
protein that positively regulates Notch signaling by ubiquitinating the Notch receptors).

Discussion
Previous studies have shown that GLI2 can modulate the expression of TGF-β
(Furler and Uittenbogaart 2012). Furthermore, we have shown that GLI2 modulates the
expression of IL-6 and IL-6R (Elsawa et al. 2011a, Jackson et al. 2015). We also
identified CD40L as a novel target of GLI2 (Figure 2-6). Furthermore, when targeting
the IL-6 in the TME in WM, we found reduced tumor growth rate and IgM secretion
(Figure 1-1, 2 and 3). These studies indicate that the interaction between malignant B
cells and bone marrow stromal cells are essential for cancer cell biology (Burger et al.
2009, Podar et al. 2008). More specifically, cytokines that are regulated by GLI2 play an
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important role in WM biology. This leads to an important finding and necessitates the
identification of novel transcriptional targets of GLI2 in bone marrow stromal cells. This
may lead to the selection of new target genes in the TME that are important in WM
biology.
Although we previously identified novel GLI2 target genes using commercially
available cytokine arrays that included 100 cytokines and their receptors, here, we
utilized RNA sequencing to investigate a broader spectrum of genes that are regulated
by GLI2 in human bone marrow stromal cells. Indeed, our preliminary analysis identified
several GLI2 target genes in L88 stromal cells (Figure 3-3).
Cep170, is a gene that encodes a 170 KDa centrosomal protein, a component of
the centrosome. Studies have shown that in human cells, Cep170 is constantly
expressed throughout the cell cycle but phosphorylated during mitosis. Cep170 can
interact with polo-like kinase 1 (Plk1) in vivo and can also be phosphorylated by Plk1 in
vitro. Furthermore, Cep170 associates with centrosomes during interphase and with
spindle microtubules during mitosis, suggesting a role of Cep170 in microtubule
organization and cell morphology (Guarguaglini et al. 2005).
AGL gene is the gene that encodes the glycogen debranching enzyme (Amylo1,6-glucosidase,4-α-glucanotransferase, AGL). AGL is mainly reported to associate with
Glycogen Storage Disease Type III (GSDIII). The deficiency in activity of AGL in the
liver and muscle causes GSD type IIIa or liver only (GSD type IIIb) (Goldstein et al.
2010). Most of the AGL mutations are nonsense mutations, but some rare missense
mutations can affect AGL function leading to GSDIII. One study found that mutations in
the carbohydrate-binding domain are more severe in nature, leading to a significant loss
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of all enzymatic activities and carbohydrate binding ability, as well as enhancing
targeting for proteasomal degradation, indicating that inactivation of enzymatic activity is
sufficient to cause GSDIII disease (Cheng et al. 2009).
VGLL3, vestigial-like 3, is a transcription factor with target genes that have a
strong association with multiple autoimmune diseases including lupus, scleroderma and
Sjögren’s syndrome and had a prominent transcriptomic overlap with inflammatory
processes in cutaneous lupus (Liang et al. 2017). VGLL3 has also been reported as a
putative transcription co-factor, involved in tumor suppressor pathway, a feature that is
characterized by the absence of VGLL3 expression in high-grade serous ovarian
carcinomas (Gambaro et al. 2013).
KIAA1109 encodes the protein KIAA1109, and its function is not yet fully
understood. It has been reported that the KIAA1109-IL2-IL21 gene region associates
with several autoimmune phenotypes (Bouzid et al. 2014). Furthermore, the
KIAA1109/Tenr/IL2/IL21 gene cluster associates with rheumatoid arthritis (Hollis-Moffatt
et al. 2010, Teixeira et al. 2009).
AKAP11 is a gene that encodes A-kinase anchor protein 11. The A-kinase
anchor proteins (AKAPs) are a group of structurally diverse proteins which have the
common function of binding to the regulatory subunit of protein kinase A (Colledge and
Scott 1999). As a member of this family, the role of AKAP11 hasn’t been thoroughly
investigated. It has been reported that AKAP11 gene polymorphism is considered as a
factor affecting peak bone mass acquisition (Correa-Rodríguez et al. 2018).
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ETNK1 gene encodes ethanolamine kinase 1 (ETNK1). ETNK1 is an
ethanolamine-specific kinase that catalyzes the first step of phosphatidylethanolamine
biosynthesis via the CDP-ethanolamine pathway (Lykidis et al. 2001). GambacortiPasserini et al performed whole exome sequencing on atypical chronic myeloid
leukemia (aCML) patients and report the presence of recurrent somatic missense
mutations in the ETNK1 gene, suggesting that the recurrent somatic ETNK1 mutations
are important in myeloproliferative/myelodysplastic disorders (Gambacorti-Passerini et
al. 2015). Furthermore, somatic missense ETNK1 mutations were found in systemic
mastocytosis with eosinophilia and chronic myelomonocytic leukemia, in addition to
aCML (Kosmider 2015, Lasho et al. 2015).
PRUNE2 encodes prune homolog 2 with BCH domain. In prostate cancer,
PRUNE2 acts as a tumor suppressor and its expression is regulated by prostate cancer
antigen 3 (PCA3), via a unique regulatory mechanism involving formation of a
PRUNE2/PCA3 double-stranded RNA, so that expression of PRUNE3 decreases or is
silenced in prostate cancer (Salameh et al. 2015). Furthermore, a whole-exome
sequencing study identified somatic mutations in PRUNE2 in parathyroid carcinoma and
recurrent mutations in kinase genes related to cell migration and invasion (Gan et al.
2015). Interestingly, PRUNE2 has also been reported to contribute to the maintenance
of the mature nervous system (Iwama et al. 2011).
NEK7 (NIMA (never in mitosis gene A-related kinase 7) belongs to the NIMA
related kinases which control the initiation of mitosis. NEK7 has been shown to be
directly involved in cytokinesis and NEK7 knockdown can cause a prometaphase arrest
of the cell cycle with monopolar or disorganized spindle. Moreover, NEK7 suppression
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in cells causes a decrease in the centrosomal γ-tubulin levels and a reduction of the
microtubule re-growth activity (Kim et al. 2007). Further studies show that depletion of
NEK7 inhibits progression through the G1 phase via down-regulation of various cyclins
and CDKs and also inhibits the earliest stages of procentriole formation, suggesting that
NEK7 is involved in the timely regulation of G1 progression, S-phase entry and
procentriole formation (Gupta et al. 2017). NEK7 has also been reported as an essential
protein acting downstream of potassium efflux (which is a common step that is essential
for NLRP3 inflammasome activation) to regulate NLRP3 inflammasome assembly and
activation (He et al. 2016, Xu et al. 2016). In hepatocellular carcinoma (HCC), NEK7
was found to be significantly overexpressed and high NEK7 expression correlated with
tumor numbers, tumor diameter, adjacent organs invasion, tumor grade and stage.
Finally, NEK7 silencing resulted in an inhibition of HCC cell growth in vitro and tumor
growth in vivo through decreasing cyclin B1 levels both in vitro and in vivo, suggesting
that NEK7 could be a novel HCC therapeutic target (Zhou et al. 2016).
IL6ST (interleukin 6 signal transducer; also known as glycoprotein 130/gp130) or
CD130 is a signal transducer shared by many cytokines, including IL-6, IL-11, IL-27 and
leukemia inhibitory factor (LIF). In particular for IL-6 signaling, IL-6 receptor family all
complex with gp130 for signal transduction and this is well established in previous
studies (Heinrich et al. 1998, Kishimoto et al. 1995). Recently studies show that
elevated intratumoral gp130 expression was associated with unfavorable survival in
gastric cancer patients (Cao et al. 2016). Loss of gp130 function can cause a novel
immunodeficiency with phenotypic similarities to STAT3 hyper-IgE syndrome (Schwerd
et al. 2017). We also previously showed that GLI2 can modulate IL-6 (Elsawa et al.
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2011b) and the IL-6Rα/gp80 (Jackson et al. 2015). The RNA sequencing data identified
gp130 as a potential target. This may be an interesting biological target for further
investigation to explore the mechanism by which GLI2 regulates gp130 in normal and
malignant B cells.
MIB1 (mind bomb E3 ubiquitin protein ligase 1) has been reported to interact with
receptor-like tyrosine kinase (RYK, which function as a transmembrane receptor for the
Wnt family of secreted protein ligands) to activate Wnt/β-catenin signaling (Berndt et al.
2011). Moreover, MIB1 has been reported to play an essential role in T cells and
marginal zone B cell development (Song et al. 2008) and in pancreatic β-cell formation
(Horn et al. 2012). Both occur through Notch signaling.
Our RNA-seq data indicate that there are other genes that are potentially
regulated by GLI2. However, additional bioinformatic and cluster analysis of the data is
needed in order to identify the most relevant candidates from a biological perspective.
Further studies should be aimed at performing additional bioinformatic analysis of the
data, validating the findings in multiple cell lines and primary cells in order to address
the role of GLI2 as a regulator of these genes in the TME. Perhaps, chromatin
immunoprecipitation (ChIP) assay followed by sequencing (ChIP-seq) experiments can
be performed and analyzed in the context of the RNA-seq data in order to identify the
novel GLI2 target genes that are directly bound by GLI2.
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Figure 3- 1. GLI2 knockdown in HS-5 bone marrow stromal cells.
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Figure 3-1: Bone marrow stromal cells HS-5 (4*106) were transfected with shRNA
targeting GLI2 (shGLI2) or scrambled control (shScr) for 2 days followed by RNA
extraction and cDNA synthesis for use to determine gene expression by qPCR as
indicated in methods. Four sets of experiments were performed, each representing a
biological replicate.
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Figure 3- 2. GLI2 knockdown in L88 bone marrow stromal cells
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Figure 3-2: Bone marrow stromal cells L88 (4*106) were transfected with shRNA
targeting GLI2 (shGLI2) or scrambled control (shScr) for 2 days followed by RNA
extraction and cDNA synthesis for use to determine gene expression by qPCR as
indicated in methods. Each set was generated from a different experiment representing
biological replicates.
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Figure 3- 3: Top 10 genes that are regulated by GLI2 identified by RNAsequencing.
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Figure 3-3: Top 10 genes that are regulated by GLI2 identified by RNAsequencing. Bioinformatic analysis of RNA-seq data in L88 cells identified genes that
are differentially expressed in the presence/absence of GLI2. The 10 genes presented
have the most fold regulation in the significantly different genes.
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DISCUSSION
Interactions between malignant B cells and stromal cells in the TME play an
essential role in regulating malignant B cell biology including cell growth, cell survival
and Ig secretion (Burger et al. 2009, Elsawa et al. 2011a, Jalali and Ansell 2016), and
cytokines in the TME play important roles in these interactions. Tocilizumab, as an antiIL-6R antibody, has been investigated in several clinical trial in patients with
inflammatory-mediated disease, including Castleman’s disease, Rheumatoid arthritis,
Systemic juvenile idiopathic arthritis, Crohn’s disease, Giant cell arteritis, Systemic
sclerosis, Systemic lupus erythematosus and multiple sclerosis (Tanaka et al. 2011).
Several studies have also investigated the addition of anti-IL-6 therapy in multiple
myeloma (MM) and report enhanced results over chemotherapeutic regimens
(Hunsucker et al. 2011, Rossi et al. 2005, Shah et al. 2016). In previous work, we have
shown that IL-6 levels are elevated in WM patients and IL-6 secreted from human bone
marrow stromal cells can promote WM cell growth and IgM secretion (Elsawa et al.
2011a, Elsawa and Ansell 2009). This finding led us to investigate the efficacy of
blocking IL-6 to block the interaction between the TME and WM cells, and evaluate the
therapeutic potential of targeting this molecule with the goal of laying the foundation for
its evaluation in clinical trials.
Our results show that targeting IL-6 in the WM TME did not affect the survival in
two WM cell line models investigated (Figure 1-1B). As reported, the role of IL-6 in WM
was shown to promote IgM secretion and WM cell growth (Elsawa et al. 2011a, Elsawa
et al. 2011b), not inducing apoptosis of WM cells (Elsawa et al. 2011b), so targeting IL-6
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did not affect the survival is not surprising. Consistent with this role, we found a
reduction in tumor growth rate when tumor bearing mice were treated with Tocilizumab
(Figure 1-2). These results indicate that targeting IL-6 in the TME in WM may slow the
rate of tumor growth. Since WM remains an incurable disease, a therapeutic drug that
slows down the rate of tumor growth may be a feasible option for WM patients.
One of the hallmarks of WM is the overproduction of monoclonal IgM protein
(Elsawa et al. 2011a, Elsawa et al. 2006, Elsawa et al. 2011b, Han et al. 2017, Jackson
et al. 2015). Our results show that tumor-bearing mice treated with Tocilizumab had
significantly reduced levels of human IgM secretion in mice serum (Figure 1-3). This
suggests that targeting IL-6 in the TME in WM may provide a much-needed
symptomatic relief for WM patients. Interestingly, RPCI-WM1 tumor-bearing mice
treated with Tocilizumab had similar levels of IgM as control mice (Figure 1-3). The 2
WM cell lines used in this study are derived from different WM patients (Chitta et al.
2013, Ditzel Santos et al. 2007). Interestingly, RPCI-WM1 cells secrete the highest
levels of IgM among the available WM cell lines, raising the possibility that the rate of
increase in IgM levels in patients may correlate with the efficacy of Tocilizumab
monotherapy. Furthermore, the differences in responses between the 2 WM cell lines
investigated may represent the natural diversity that exists between various patients.
Therefore, an examination of the efficacy of IL-6 therapy in WM patients is necessary to
evaluate its effect on IgM levels and tumor growth.
Current therapies used for the treatment of WM patients mainly focus on
targeting cancer cells directly using monotherapy or combination therapies, such
treatments including ibrutinib (the only drug approved by FDA for WM patients),
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Rituximab (in combination with CHOP; R-CHOP), Bendamustine, Dexamethasone,
Fludarabine, Chlorambucil, Everolimus, among others (Kapoor et al. 2015). Our results
show that targeting IL-6 in the TME can reduce the rate of WM cell growth and the
secretion of IgM, but not enhance survival or induce cell death (Figure 1-1, 2, and 3).
This is consistent with previous studies that showed IL-6 has no effect on WM cell
survival but modulates cell growth and IgM secretion (Elsawa et al. 2011a, Elsawa et al.
2011b). Future studies that investigate the efficiency of combination of targeting the
TME and cancer cells together will therefore shed more light on the potential of
Tocilizumab in WM. Combined targeting of IL-6, which slows WM cell growth and
reduces IgM secretion, and malignant cells, which induces apoptosis of WM cells, may
prove to be effective and provide therapeutic benefit to patients.
In bone marrow malignancies such as multiple myeloma (MM) and Waldenström
macroglobulinemia (WM), bone marrow stromal cells play an important role in malignant
cell biology by secreting a variety of cytokines that are used by malignant cells to
survive and proliferate (Azab et al. 2012b, Burger et al. 2009, Burger and Peled 2009,
Cheung and Van Ness 2001, Elsawa et al. 2011b, Kurtova et al. 2009a). Previous
studies have shown that GLI2 can modulate the expression of TGF-β (Furler and
Uittenbogaart 2012). Furthermore, we have shown that GLI2 modulates the expression
and secretion of IL-6 and IL-6R (Elsawa et al. 2011a, Jackson et al. 2015). When
targeting the IL-6 in the TME in WM, we found reduced tumor growth rate and IgM
secretion (Figure 1-1, 2 and 3). These studies indicate that the interaction between
malignant B cells and bone marrow stromal cells are essential for malignant B cell
biology (Burger et al. 2009, Podar et al. 2008). More specifically, cytokines that are
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regulated by GLI2 play important roles in WM biology. This leads to an important finding
and necessitates the identification of novel transcriptional targets of GLI2 in bone
marrow stomal cells. This may lead to the selection of new target genes in the TME that
are important to WM cells.
Here, we focused our studies on the molecular mechanism of cytokine regulation
by the oncogenic transcription factor GLI2. The results from our initial screening of
cytokines potentially modulated by GLI2 identified several cytokines that are
differentially regulated by GLI2 (Figure 2-1). Among those, CD40L was identified as a
new novel GLI2 target gene (Figure 2-1). CD40L is an important cytokine that has been
shown to play an important role during normal B cell responses where it regulates B cell
growth, survival, antibody secretion as well as class switch recombination (CSR)
(Wykes 2003). In addition to its role in normal B cell functions, it has also been shown to
modulate malignant B cells (Burger and Gandhi 2009, Fiumara and Younes 2001,
Tournilhac et al. 2006). Therefore, understanding the mechanism of its regulation is
important to further our understanding of normal and malignant B cells responses.
We found that the oncogenic transcription factor GLI2 induces the expression of
CD40L in stromal cells (Figure 2-2). Moreover, we found that GLI2 modulates CD40L
expression by directly binding to its promoter (Figures 2-3 & 4). Our data identified
CD40L as a novel direct target of the GLI2 transcription factor in human bone marrow
stromal cells (Figures 2-1, 2 and 3). Our group has shown that GLI2 can directly target
the IL-6 promoter in bone marrow stromal cells and lead to increased IL-6 expression
and secretion (Elsawa et al. 2011a). We also demonstrated a direct role for GLI2 in
regulating IgM secretion by WM cells (Jackson et al. 2015). Therefore, this study
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identifies CD40L as a novel GLI2 target gene and suggests a novel mechanism by
which GLI2 modulates malignant B cell biology via modulation of the TME.
Previous studies have shown that CD40L expression on mast cells in the TME
promotes CD40 signaling on primary WM B cells (Tournilhac et al. 2006). Our data
support these studies showing GLI2-mediated CD40L increases WM B cell activation
(as evidenced by Erk phosphorylation) (Figure 2-1C) and ultimately increased
malignant B cell proliferation (Figure 2-1D) upon co-culture with stromal cells stably
expressing CD40L. We also show that GLI2 induces an increase in sCD40L and
conditioned media from ΔN-GLI2 transfected stromal cells induced an increase in WM
cell proliferation (Figure 2-2F and 2G). The increase in proliferation was modest (1213%), which did not allow us to observe a statistical difference in WM cell proliferation in
the presence of CD40L blocking antibodies, although the trend was consistent with, at
least, a partial role for sCD40L (data not shown). In a previous study we have shown
that the CCR3-PI3K-AKT signaling pathway is a regulator of GLI2 (Elsawa et al. 2011a).
Here, we found that the CCR3-PI3K-AKT signaling pathway can also modulate CD40L
expression and promoter activity and this regulation of CD40L requires an intact GLI2
(Figure 2-5).
In summary, our studies demonstrate a novel role for GLI2 in promoting
malignant B cell activation and proliferation via regulation of CD40L expression in the
TME and signaling through the CCR3-PI3K-AKT pathway can modulate CD40L
expression and promoter activity and this regulation requires an intact GLI2 (Figure 26C). These studies define the molecular mechanism by which GLI2 regulates CD40L
expression in human bone marrow stromal cells. Further investigation of GLI2 target
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genes will expand our understanding of the role of GLI2 in modulating inflammatory
cytokines in the TME.
A role for CD40L has been described in mantle cell lymphoma (MCL) where
CD40L promotes activation and proliferation of MCL cells (Andersen et al. 2000).
Similarly, a role for CD40L/CD40 signaling has been described in Hodgkin lymphoma, B
cell lymphoma, chronic lymphocytic leukemia and other hematological neoplasms
(Aldinucci et al. 2012, Burger and Gandhi 2009, Fiumara and Younes 2001, Jin et al.
2004, Schattner 2000, Srahna et al. 2001, Tong et al. 2000, Tournilhac et al. 2006,
Tsirakis et al. 2012, Voorzanger-Rousselot et al. 1998, Younes 2001). Despite the
importance of CD40L-CD40 signaling in normal and malignant B cells, little is known
about the mechanisms that regulate CD40L expression. The identification of GLI2 as a
regulator of CD40L promoter advances our understanding of the regulation of this
important cytokine.
In human T cells, several transcription factors including AP-1, NF-AT and NF-κB
have been shown to modulate CD40L (Srahna et al. 2001). These transcription factors
regulate a region closer to the transcription start site. Here we show that GLI2 can
directly bind to the promoter of CD40L (binding site 1: -1478, Figure 2-3A). This region
is located further upstream from the regulatory regions of these other transcription
factors. It would be interesting in future studies to address whether GLI2 corporates with
AP-1, NF-AT and NF-κB to regulate CD40L expression.
The role of GLI2 as a transcription factor has been widely studied. Several
downstream targets that are regulated by GLI2, such as TGF-β (Furler and
Uittenbogaart 2012), IL-6 (Elsawa et al. 2011a), IL-6Rα (Jackson et al. 2015) and
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CD40L (Han et al. 2017) have been characterized. Moreover, GLI2 is directly involved
in driving melanoma invasion and metastasis (Mauviel et al. 2010) and plays a critical
role in maintaining the tumorigenic properties of prostate cancer cells (Thiyagarajan et
al. 2007). We have identified several other genes that are potentially regulated by GLI2
(Figure 2-1 and Figure 3-3). Further analysis of the mechanism by which GLI2
modulates these genes and their role in cancer cell biology will be important for our
understanding of the role of GLI2 in regulating inflammation in the TME.
In our study, we investigated a GLI2-target gene in the TME, IL-6, as a
therapeutic target to study the effect of disrupting the crosstalk between cancer cells
and the TME. The outcome of targeting IL-6 reduced human IgM secretion and slowed
down tumor growth rate of WM B cells. However, this did not affect mice survival
(Figure 1-1, 2 and 3). This leads to the question of whether we can switch from
targeting the genes regulated by GLI2 to targeting the transcription factor GLI2 itself.
Currently, several studies focus on targeting different transcription factors that
play critical roles in cancer biology. Hypoxia-inducible factor 1 (HIF-1) regulates genes
that are involved in cancer biology, which including angiogenesis, cell survival, glucose
metabolism and invasion, and in preclinical studies, inhibition of HIF-1 activity has
marked effects on tumor growth. Therefore, HIF-1 can be used as a potential
therapeutic target (Semenza 2003). Forkhead O (FOXO) transcription factors play an
essential role in the regulation of cellular functions such as cell cycle arrest, cell death,
and protection form stress stimuli, and inactivation of FOXO protein is associated with
several neoplasms including breast cancer, prostate cancer, glioblastoma,
rhabdomyosarcoma and leukemia. Moreover, clinical studies have shown therapeutic
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benefit from using drugs like paclitaxel, imatinib, and doxorubicin that activate FOXO
targets (Yang and Hung 2009). The transcription factor NF-ƙB is frequently encountered
in tumor cells and contributes to aggressive tumor growth and resistance to
chemotherapy and radiation during cancer treatment. Accumulating evidence shows
that induction of chemoresistance and radioresistance are mediated by several genes
regulated by NF-ƙB and inhibition of NF-ƙB increases sensitivity of cancer cells to
chemotherapeutic agents and radiation exposure. Therefore, targeting NF-ƙB may be a
potential therapeutic strategy to overcome chemoresistance and radioresistance in
cancer treatment (Li and Sethi 2010). In addition, transcription factors from the STAT
family (STAT3 and STAT5), are important players in human cancers and are validated
targets for therapeutic intervention (Libermann and Zerbini 2006, Redell and Tweardy
2005).
Inhibition of Smoothened, the signal transduction subunit of the Hedgehog (HH)
receptor initially identified GLI2 as a transcriptional activator and has been shown to
abrogate leukemia stem cell dormancy and reduce the dormant leukemia stem cells
burden using a clinical antagonist (Sadarangani et al. 2015). This suggests that
smoothened inhibition can provide therapeutic efficacy in cancer patients. Currently,
there are two Smoothened inhibitors (Vismodegib and Sonidegib) that have been
approved by the FDA (Rimkus et al. 2016). However, since GLI proteins can also be
activated through HH signaling-independent mechanisms, this raises the possibility that
targeting GLI may be more therapeutically beneficial than targeting HH.
Direct inhibition of GLI has gained interest and shows promise to target these
transcription factors and their targets. In malignant pleural mesothelioma, inhibition of
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GLI by siRNA or a novel small molecule GLI inhibitor suppressed tumor cell growth
dramatically both in vitro and in vivo. Furthermore, inhibition of GLI exhibited better
cytotoxicity than inhibition of Smoothened, suggesting that inhibition of GLI function
could be a strong novel and effective approach to treat malignant pleural mesothelioma
(Li et al. 2013). In acute myeloid leukemia, inhibition of GLI by GLI inhibitor GANT61
causes growth arrest and apoptosis in human myeloid leukemia cell lines (Pan et al.
2012). Lauth et al screened for small-molecule antagonists of GLI-mediated
transcription and revealed two molecules that can selectively inhibit GLI-mediated gene
transactivation by acting in the nucleus to block GLI function, and one of them interferes
with GLI1 DNA binding in living cells. More importantly, these compounds efficiently
inhibited in vitro tumor cell proliferation and successfully blocked cell growth in an in
vivo xenograft model using human prostate cancer cells (Lauth et al. 2007)
This suggests that directly targeting GLI2 in cancer cells may provide therapeutic
efficacy. Future studies in WM and other neoplasms should focus on investigating the
therapeutic efficacy of targeting GLI. Furthermore, combined targeting of cancer cells,
cells in the TM, and/or molecules such as cytokines, which mediate the interaction
between these cells may be beneficial for cancer patients.
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Sherine Elsawa
Biological Sciences

RE: Review of Application for Continuing Approval
The following application for continuation of approval of the use of live vertebrate animals in research was reviewed
and approved by the Institutional Animal Care and Use Committee by designated member review on 15-Jul-2016:

Title: Targeting the tumor microenvironment in cancer

ORC #: LA12-0007

This approval will be effective for one year from 16-Jul-2016 until 15-Jul-2017. It is your responsibility as
principal investigator to implement the research/course as specified in your IACUC protocol. If there is a change in
the project, a need for additional animals, or if the project will last beyond that date, you will need additional
approval and should contact the Office of Research Compliance, Integrity and Safety at 753-8588.
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